Measuring health-related quality of life (HRQoL) and quality-adjusted life years (QALY) in the critical care setting by Vainiola, Tarja
Hjelt Institute, Department of Public Health,  
and 
Hospital District of Helsinki and Uusimaa, Group administration 
Faculty of Medicine, University of Helsinki 
 
 
 
 
 
 
 
Measuring health-related quality of life (HRQoL) and quality-adjusted life years (QALY) in 
the critical care setting 
 
Tarja Vainiola 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
To be presented, with the permission of the Faculty of Medicine of the University of Helsinki, 
for public examination in Auditorium XV, University Main Building,  
Unioninkatu 34, on May 24
th
 2014 
 
Helsinki 2014 
 
2 
 
Supervised by:  
Professor (emeritus) Harri Sintonen, Ph.D. 
Hjelt Institute 
Department of Public Health 
University of Helsinki 
Professor Risto P. Roine, M.D., Ph.D. 
University of Eastern Finland  
Department of Health and Social Management  
Research Centre for Comparative Effectiveness and Patient Safety (RECEPS) 
 
Chief Physician  
Helsinki and Uusimaa Hospital District  
Research and Development  
 
Reviewed by: 
Professor Tero Ala-Kokko, M.D., Ph.D.  
Oulu University Hospital  
Department of Anesthesiology  
Division of Intensive Care Medicine 
Oulu, Finland  
Adjunct Professor Juha Laine, Ph.D.  
Pfizer Oy  
Helsinki, Finland 
 
Official opponent: 
Professor  (emeritus) Martti Kekomäki, Ph.D.  
Faculty of Medicine  
University of Helsinki 
  
 
 
 
ISBN 978-952-10-9810-9 (Paperback) 
ISBN 978-952-10-9811-6 (PDF) 
 
Unigrafia, Helsinki, 2014  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
                To Aada, Lukas and grandchildren yet to come 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Table of Contents 
Summary........................................................................................................................................................ 7 
Tiivistelmä ..................................................................................................................................................... 9 
List of original publications ......................................................................................................................... 11 
Abbreviations .............................................................................................................................................. 13 
1. Introduction ............................................................................................................................................. 15 
2. Review of the literature ........................................................................................................................... 17 
2.1 Generic, single-index health-related quality of life instruments ........................................................ 17 
2.1.1 The EQ-5D ..................................................................................................................................... 19 
2.1.2 The 15D .......................................................................................................................................... 21 
2.1.3 Comparison of the EQ-5D and the 15D in different patient populations ....................................... 23 
2.2 Quality-adjusted life years ................................................................................................................. 24 
2.2.1 The calculation of QALYs ............................................................................................................. 25 
2.3 Critical care ....................................................................................................................................... 27 
2.3.1 Critical care patients’ survival ........................................................................................................ 27 
2.3.2 The costs of critical care ................................................................................................................. 28 
2.3.3 HRQoL measurement in critical care patients ................................................................................ 30 
2.3.4 QALY calculation in the critical care setting ................................................................................. 31 
2.4 Summary of the literature .................................................................................................................. 33 
3. Aims of the study ..................................................................................................................................... 34 
4. Patients and methods ............................................................................................................................... 35 
4.1 Patients .............................................................................................................................................. 35 
4.2 Methods ............................................................................................................................................. 36 
4.2.1 HRQoL ........................................................................................................................................... 36 
4.2.2 QALY calculation........................................................................................................................... 38 
4.2.3 Statistical methods .......................................................................................................................... 39 
4.2.4 Assessment of other parameters ..................................................................................................... 42 
5. Results ..................................................................................................................................................... 44 
5.1 Patients .............................................................................................................................................. 44 
5.2 Agreement on HRQoL scores between the EQ-5D and the 15D ...................................................... 45 
5.3 Comparison of the discriminatory power and responsiveness between the EQ-5D and the 15D ..... 46 
5.4 The effect of the HRQoL instrument on the number of QALYs ....................................................... 47 
5.5 The effect of the calculation method on the number of QALYs and the cost per QALY ratio ......... 47 
5.6 The effect of excess mortality and follow-up time on the extrapolated life expectancy ................... 48 
5.7 The ability of the indicators predicting mortality to predict follow-up HRQoL ............................... 48 
6 
 
6. Discussion................................................................................................................................................ 50 
6.1 Main results ....................................................................................................................................... 50 
6.2 The discriminatory power and responsiveness to change of the EQ-5D and the 15D ...................... 50 
6.3 Calculating QALYs ........................................................................................................................... 51 
6.4 Baseline HRQoL in the critical care setting ...................................................................................... 52 
6.5 Problems concerning negative HRQoL scores .................................................................................. 52 
6.6 The time horizon used in QALY calculations ................................................................................... 53 
6.7 Factors affecting the follow-up HRQoL ............................................................................................ 54 
6.8 Limitations of the study ..................................................................................................................... 55 
6.9 Clinical implications .......................................................................................................................... 56 
6.10 Future studies ................................................................................................................................... 56 
7.  Conclusions ............................................................................................................................................ 58 
Acknowledgements ..................................................................................................................................... 59 
References ................................................................................................................................................... 60 
Original publication ...................................................................... Virhe. Kirjanmerkkiä ei ole määritetty. 
 
  
7 
 
Summary 
Background: Cost-utility analysis provides a means to determine the health benefit and economic burden of 
different health-care interventions. In cost-utility analyses, the benefit of care is measured in quality-adjusted 
life years (QALYs) gained. The calculation of QALYs requires knowledge of the change in health-related 
quality of life (HRQoL) and assumptions concerning when the benefit of care materialises and how long the 
benefit lasts. The gold standard for QALY calculations has not yet been defined and, as a consequence, the 
HRQoL instruments and calculation methods used vary from study to study. 
Aims: The aim of the current study was to clarify how much the differences in the components used for the 
calculation of QALYs are reflected in the end result, i.e., the number of QALYs gained in the critical care 
setting. The detailed aims were to study 1) the effect of the instrument used (the EQ-5D or the 15D) on the 
HRQoL score and the measured changes in it; 2) the effects of the baseline HRQoL and the assumptions 
concerning the progress of recovery on the number of QALYs; 3) how to estimate life expectancy in the 
critical care setting, and 4) which factors have an effect on the follow-up HRQoL. 
Patients and methods: The results are based on two study populations. The first population comprises 
patients having been treated in an intensive care or high-dependency unit (N = 3600), and whose HRQoL 
was assessed using the EQ-5D and 15D HRQoL instruments 6 and 12 months after treatment. The second 
population consists of patients having undergone treatment in a cardiac surgery intensive care unit (N = 980), 
and whose HRQoL was assessed using the 15D HRQoL instrument at baseline, when placed on a waiting list 
for surgery and 6 months after treatment.  
Main results: The results of the studies show that the HRQoL index score is dependent on the instrument 
used. The distribution of the patients’ HRQoL scores differed between instruments. The differences are 
explained, inter alia, by the ceiling effect of the EQ-5D—i.e., for a significant proportion of the respondents, 
the instrument produced the best possible HRQoL score of 1—and by the negative scores of the EQ-5D — 
i.e., for health states worse than death. The 15D produced higher mean HRQoL scores than the EQ-5D. The 
15D was able to distinguish between a greater number of health states than the EQ-5D, thus showing a better 
discriminatory power.  
The choice of instrument was also reflected in the change observed in HRQoL. The two instruments 
classified patients according to the change in HRQoL (improved, remained stable, deteriorated) in a similar 
manner only in approximately half of the cases. The 15D was more sensitive to detecting a change than the 
EQ-5D. Consequently, both its discriminatory power and responsiveness to change were better than those for 
the EQ-5D. 
The assumptions concerning the progression of recovery and the baseline HRQoL score had an effect on the 
number of QALYs gained both within and between instruments and, consequently, on the cost per QALY 
ratio. The EQ-5D and the 15D performed differently under different calculation assumptions. The greatest 
difference in the number of QALYs gained was caused by the negative HRQoL scores observed with the 
EQ-5D enabling the accrual of more than 1 QALY per year.  
Patients having been treated in an intensive care unit showed long-lasting excess mortality and, as a 
consequence, a reduced life expectancy. By contrast, in cardiac surgery patients, the life expectancy was 
similar to or even better than that of the general population. In patient groups with excess mortality, neither 
the follow-up time nor the life expectancy of the general population can be regarded as optimal indicators for 
the duration of the benefit of care. In those patient groups, life expectancy should be extrapolated in relation 
to the observed excess mortality. 
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In cardiac surgery patients, factors predicting mortality and morbidity are not able to accurately predict the 
follow-up HRQoL. Instead, patient experiences, such as restlessness and pain during intensive care, 
predicted poor post-treatment HRQoL. Given that these results are novel, future studies should be directed to 
patient experiences during treatment. They may be confounding factors in analyses concerning treatment 
effectiveness, and also diminish the effectiveness of treatment.  
Conclusion: QALY is not a universal measure, but is dependent on the HRQoL instrument used and on how 
the factors to be taken into account in the calculation of QALYs are chosen and defined. Furthermore, factors 
external to the interventions under evaluation, such as the patient’s psychological experiences during 
treatment, may have an effect on the follow-up HRQoL. The ranking of different interventions in terms of 
their effectiveness calls for standardisation in the calculation of QALYs and more information on the effect 
of patient experiences during treatment on the follow-up HRQoL 
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Tiivistelmä 
Tausta: Kustannus-utiliteettianalyysien avulla voidaan selvittää terveydenhuollon eri interventioiden 
terveyshyötyjä ja kustannuksia. Näissä analyyseissa hoidon hyödyt mitataan laatupainotettuina 
lisäelinvuosina (QALY). QALY:n laskemiseen tarvitaan tieto terveyteen liittyvän elämänlaadun muutoksesta 
sekä oletus toipumisen kulusta ja hoidon tuottaman hyödyn kestosta.  Toistaiseksi ei ole määritelty kultaista 
standardia QALY:n laskemiselle, minkä seurauksena käytetyt elämänlaatumittarit ja laskentatavat 
vaihtelevat. 
Tavoite: Tämän tutkimuksen tarkoituksena on selvittää, missä määrin erot laatupainotetun elinvuoden 
laskemisen osatekijöissä vaikuttavat saavutettujen laatupainotettujen elinvuosien määrään 
tehohoitoympäristössä. Tutkimuksen yksityiskohtaiset tavoitteet ovat selvittää 1) tuottavatko EQ-5D ja 15D 
samanlaisen arvion potilaiden terveyteen liittyvästä elämänlaadusta ja elämänlaadun muutoksesta; 2) mikä 
on lähtötilanteen elämänlaadun ja toipumisen kulkuun liittyvien erilaisten oletusten vaikutus saavutettujen 
laatupainotettujen elinvuosien määrään; 3) miten elinajanodote tulisi arvioida tehohoitopotilailla; ja 4) mitkä 
tekijät ennustavat seuranta-ajan terveyteen liittyvään elämänlaatua. 
Aineisto ja menetelmät: Väitöskirja koostuu kahdesta aineistosta. Ensimmäinen aineisto käsittää teho- ja 
valvontaosastoilla hoidettuja potilaita (n=3600), joiden terveyteen liittyvä elämänlaatu mitattiin EQ-5D ja 
15D elämänlaatumittareilla kuusi ja 12 kuukautta hoidon jälkeen. Toinen aineisto koostuu sydänkirurgian 
teho-osastolla hoidetuista potilaista (n=980), joiden terveyteen liittyvä elämänlaatu mitattiin 15D 
elämänlaatumittarilla hoitojonoon asettamisen yhteydessä ja kuusi kuukautta hoidon jälkeen.  
Päätulokset: Tutkimuksen tuloksena todettiin, että terveyteen liittyvää elämänlaatua osoittava indeksiluku 
on riippuvainen käytetystä elämänlaatumittarista. Mittarien tuottamien elämänlaatuindeksien jakaumat 
erosivat toisistaan. EQ-5D:llä oli taipumus kattoefektiin eli varsin suuri osa vastaajista sai mittarilla 
maksimiarvon (=1), mikä tarkoittaa, että terveyteen liittyvä elämänlaatu olisi paras mahdollinen (täysin 
terve). Lisäksi EQ-5D tuotti negatiivisia elämänlaatuindeksejä eli elämänlaadun tiloja, jotka kuvastavat 
kuolemaa heikompaa elämänlaatua. 15D tuotti keskimääräisesti korkeampia elämänlaadun indeksejä. Se 
pystyi paremmin erottelemaan elämänlaadun eri tiloja kuin EQ-5D eli sen erottelukyky oli parempi.  
Käytetty elämänlaatumittari vaikutti myös terveyteen liittyvässä elämänlaadussa havaittuun muutokseen. 
Mittarit luokittelivat potilaat elämänlaadun muutoksen suhteen (parantunut, ennallaan, heikentynyt) samalla 
lailla noin puolessa tapauksista. 15D oli herkempi havaitsemaan elämänlaadun muutosta kuin EQ-5D. Näin 
ollen sekä erottelukyky että muutosvaste olivat 15D:llä parempia kuin EQ-5D:llä. 
Oletukset toipumisen kulusta ja käytetty lähtötilanteen elämänlaatuindeksin arvo vaikuttivat mittarien sisällä 
ja välillä saavutettuihin laatupainotettuihin elinvuosiin ja sitä kautta kustannukset/QALY -suhteeseen. EQ-
5D ja 15D toimivat erilailla eri laskentaoletuksilla. Suurimman eron saavutettuihin laatupainotettuihin 
elinvuosiin aiheutti EQ-5D:n negatiiviset elämänlaatuindeksit arvot, jotka mahdollistavat enemmän kuin 
yhden laatupainotetun elinvuoden kertymisen vuoden aikana.  
Tehohoitopotilailla havaittiin kauan jatkuva ylikuolleisuus väestöön verrattuna ja ylikuolleisuuden 
seurauksena alentunut elinajanodote. Sydänkirurgisilla potilailla elinajanodote sen sijaan vastasi väestön 
elinajanodotetta, tai oli jopa sitä parempi. Tautiryhmissä, joissa havaitaan ylikuolleisuutta, seuranta-aika ja 
väestön elinajanodote eivät ole optimaalisia hoidon hyödyn keston suureita. Näissä tautiryhmissä 
elinajanodote tulisi ekstrapoloida suhteessa havaittuun ylikuolleisuuteen.  
Sydänkirurgisilla potilailla sairastavuutta ja kuolleisuutta kuvastavat indikaattorit eivät ennustaneet seuranta-
ajan terveyteen liittyvää elämänlaatua. Sen sijaan tehohoidon aikainen levottomuus ja kivuliaisuus ennustivat 
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hoidon jälkeistä alentunutta elämänlaatua. Koska tulokset ovat uusia, tulee tutkimusta suunnata edellä 
mainittuihin ja muihin potilaan hoidon aikaisiin kokemuksiin, jotka saattavat olla sekoittavia tekijöitä hoidon 
vaikuttavuutta arvioitaessa ja heikentää hoidon tuloksellisuutta. 
Johtopäätös: Laatupainotetut elinvuodet eivät ole universaali mittayksikkö, vaan riippuvainen käytetystä 
elämänlaatumittarista ja siitä, miten laskennassa huomioon otettavat osatekijät on määritelty ja valittu. 
Lisäksi arvioitavien hoitomuotojen ulkopuoliset tekijät, kuten potilaan hoidonaikaiset kokemukset, saattavat 
vaikuttaa koettuun elämänlaadun muutoksen.  Eri hoitomuotojen asettaminen paremmuusjärjestykseen 
vaikuttavuuden suhteen edellyttää laatupainotettujen elinvuosien laskennan standardointia ja lisää tietoa 
potilaiden hoidonaikaisten kokemusten vaikutuksesta elämänlaadun muutokseen.  
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1. Introduction 
The development of new treatment methods and the reorganisation of functions have led to an 
ongoing change in the organisation of health-care services. Many interventions formerly requiring inpatient 
care are now performed as day surgeries while increasingly demanding interventions become available. As a 
consequence, a continually growing number of hospital days comprise of days spent in an intensive care 
environment. For example, in the United States between 2000–2005, the number of acute care hospital beds 
decreased and, at the same time, the number of critical care beds increased, resulting in a situation where 
15% of all hospital beds were situated in a critical care environment. As a consequence, the number of 
critical care inpatient days increased by 10.6% (Halpern and Pastores, 2010). 
In addition to the reorganisation of services, the ageing of the population also increases the 
demand for critical care. The elderly (≥65 years of age) use more critical care compared to the younger 
population (<65 years). In Minnesota, the elderly were reported to have used a mean of 125.3 ICU 
days/1 000 person years compared to 17.1 ICU days/1 000 person years in the younger population (Seferian 
and Afessa, 2006). In Finland, the annual growth of hospital days in critical care setting has been 
concentrated on the elderly population (older than 65 years). This trend has been steadily increasing in recent 
years (Figure 1). The elderly account for about 40% of all inpatient days in critical care settings (Intensium 
benchmarking database).  
 
 
 
 
Figure 1. Growth rate of hospital days in the critical care setting by age in Finland, 2004–2012 
 
For example, in Finland, the proportion of individuals 65-years-old and older has grown 21% 
from 2000 to 2010. In 2040, the number of elderly is predicted to grow by more than 660 000 individuals, 
i.e., 70% more than the number of elderly in 2010 (Statistics Finland, database). Age as such does not 
generate a need for intensive care; but, since it is associated with an increased prevalence of chronic 
illnesses, the ageing of a population leads to an increased need for ICU days (Seferian and Afessa, 2006).  
Intensive care requires substantial personnel and financial resources. The cost of an inpatient 
day in a critical care setting is many fold compared to an inpatient day in a normal ward. For example, the 
cost of an inpatient day in a normal ward of the Helsinki University Hospital in 2013 ranged from 300 € to 
900 €, while in ICU, the range was from 2 700 € to 4 300 €. According to the Intensium benchmarking 
database, there were about 57 000 inpatient days in critical care settings in 2012. In annual costs, this 
amounts to about 201 € million (an inpatient day costs 3 500 €) (Intensium benchmarking database). 
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The increasing demand for intensive care together with its resource intensity mandates the 
assessment of its health gains measured by QALYs. The calculation of QALYs requires knowledge on 
patients’ health-related quality of life (HRQoL), the change in it, knowledge on or at least assumptions about 
when the benefit of care materialises and how long the benefit lasts.  
HRQoL can be measured by disease-specific or generic HRQoL instruments. But, for QALY 
calculations and cost-utility analyses, generic HRQoL instruments are recommended since they allow, at 
least in theory, comparisons between different illnesses and their treatments. Widely known generic HRQoL 
instruments that produce a single index score on a 0–1 scale required for QALY include the Assessment of 
Quality of Life (AQoL) (Hawthorne et al., 1999), the Health Utilities Index (HUI1, HUI2 and HUI 3) 
(Furlong et al., 2001), the SF-6D (Brazier et al., 2002), the EQ-5D (Brooks and the EuroQol Group, 1996) 
and the 15D (Sintonen, 1994; Sintonen, 1995). As mentioned earlier, in addition to the HRQoL score, the 
duration of the benefit of care and the assumption about the progress of recovery, i.e., the way the change 
occurs in the HRQoL score over time, are crucial elements in QALY calculations.  
The special characteristics of the measurement of HRQoL and the calculation of QALYs 
within critical care settings require contemplation. First, although no HRQoL instrument can claim to be the 
gold standard, the 2002 Brussels Roundtable Consensus Meeting recommended the SF-36 and the EuroQol 
(EQ-5D) as the preferred HRQoL instruments in the critical care setting (Angus and Carlet, 2003). Second, 
the baseline HRQoL usually has an effect on the follow-up HRQoL score; but, its measurement or estimation 
in acutely ill critical care patients is challenging (Manca et al., 2005). Third, the effect of a serious illness on 
life expectancy is often vague and difficult to establish, which poses a major problem as the time horizon 
used in QALY calculations, e.g., the remaining lifetime of the patient, is uncertain. The aim of the current 
study was to clarify how much the differences in the components used for the calculation of QALYs are 
reflected in the end result, i.e., the number of QALYs gained in the critical care setting. 
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2. Review of the literature 
2.1 Generic, single-index health-related quality of life instruments 
Generic, single-index HRQoL instruments have been developed in many countries. The 
AQoL was developed in Australia at the end of the 1990s (Hawthorne et al., 1999), the EQ-5D by European 
collaboration in the early 1990s (Brooks and the EuroQol Group, 1996) and the 15D in Finland in the early 
1980s (Sintonen, 1994; Sintonen, 1995). The Health Utilities Index (HUI) system, which was developed in 
Canada in the 1980s (Furlong et al., 2001), comprises three different instruments (HUI1, HUI2 and HUI3), 
of which HUI2 and HUI3 are complementary and can be used in parallel. The SF-6D is derived from the 
profile instrument SF-36, which was developed in the United States (Hay and Morales, 2001). The 
development process of the SF-36 began in the 1980s and the final version was introduced in 1990 (Ware, 
2000). The revision and algorithm development for a generic, single-index score HRQoL instrument from 
the SF-36 was completed in the United Kingdom in the early 2000s (Brazier et al., 2002) 
 All generic HRQoL instruments consist of two elements: the health state descriptive system 
and the valuation system of health states defined by the health state descriptive system. In the QALY 
context, HRQoL must be expressed as a single-index score, where 1 represents full health and 0 represents 
death; some instruments, however, also produce negative scores, which imply health states worse than death 
(WTD). 
 
The health state descriptive system 
As the expression suggests, the aim of the health state descriptive system is to describe all 
essential dimensions of health from the viewpoint of HRQoL. In practice, the health state descriptive system 
is a standardised, self-administered questionnaire. There is no generally accepted theory of HRQoL to 
determine which dimensions to include in the health state descriptive system. Many systems have their roots 
in the classic definition of the World Health Organization (WHO), according to which “health is a state of 
complete physical, mental and social well-being, and not merely the absence of disease or infirmity” (WHO, 
1958). Since this definition is quite broad, the aspects of physical, mental and social well-being have been 
operationalised in different ways and, as a consequence, the health state descriptive systems differ between 
the instruments (Sintonen, 1994; Sintonen, 1995; Brooks and EuroQol Group, 1996; Hawthorne et al., 1999; 
Furlong et al., 2001; Hay and Morales, 2001; Brazier et al., 2002). However, the dimensions and their 
content should be restricted to those upon which health care can have an effect.  
The health state valuation system 
 
The aim of the health state valuation system is to establish population preferences—i.e., 
quality weights—for the different health states defined by the health state descriptive system. The valuation 
can take place by following a direct and holistic or indirect approach. Typically, in the direct and holistic 
approach, the health states to be valued are described in written form in their entirety to those from whom the 
valuations are elicited (the respondents) who must imagine themselves in those hypothetical states even if the 
valuation takes place in different ways. Using the indirect approach, the valuation is divided into parts or 
stages and the final HRQoL scores for different health states are aggregated from the results of those stages.  
The most frequently used valuation methods are the Visual Analogue Scale (VAS) also called 
the Rating Scale (RS), Magnitude Estimation (MG), Standard Gamble (SG), Time Trade-Off (TTO), Person 
Trade-Off (PTO) and Willingness-to pay (WTP) (Grabbe et al., 1997; Green et al., 2000). Normally, in direct 
valuation methods, a limited number of relatively simple health states are valued directly and the single-
index score for most of the health states is extrapolated by statistical methods (Kopec and Willison, 2003).  
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The minimal clinically important change 
The minimal clinically important change i.e., the magnitude of a change in the HRQoL score 
that a patient can perceive as a change for better or worse can be regarded as an indicator of the effectiveness 
of care (Walters and Brazier, 2005). Estimates for it have been derived using two different methods — a 
distribution-based method or an anchor-based method. Distribution-based measures are effect size (ES), 
standardised response mean (SRM) and standard error of mean (SEM). When estimating the change using 
distribution-based methods, the distribution of the data has an effect on the results (King, 2011). In the 
anchor-based method, the change is combined with an external anchor. The external anchor can be a 
patient’s opinion about the development of HRQoL or a clinical measurement or indicator, which expresses 
the development of the illness (Wyrwich, 2004). The development of HRQoL is established by asking the 
patient whether s/he has experienced an improvement, no change or deterioration in her/his health compared 
with the former measurement point (Browne et al., 2010). The anchor-based method is considered more 
appropriate for estimating a change than distribution-based methods (Revicki et al., 2008).  
In the literature, the minimal clinically important change is usually referred to with the 
acronym MCID (minimal clinically important difference) or with MID (minimal important difference) 
(Wyrwich, 2004). Conceptually, however, minimal clinically important change and minimal clinically 
important difference are distinct. The former refers to a change over time—e.g., in a group of patients—
whereas the latter refers to a difference in a cross-section — e.g., between two groups. The former can be 
estimated using the methods described above, whereas there is no direct method to estimate the latter. 
Therefore, the latter is considered equal to the former and both are referred to with acronyms MCID or MID 
(Table 1). 
 
Table 1. Properties of the generic, single index HRQoL instruments 
 AQoL
1
 EQ-5D
2
 15D
3
 HUI2
4
 HUI3
4
 SF-6D
5
 
Origin Australia Europe Finland Canada Canada USA 
Items 35 5 15 7 8 36
6
 
Response 
levels 
4-6 3 5 3-5 5-6 2-6 
Range -0.04-1 -0.59-1 0-1 -0.03-1.00 -0.36-1 0.203-1 
Valuing 
system 
TTO TTO RS SG SG SG 
Different 
health states 
2.37*10
23
 243 3.1*10
10
 24 000 972 000 8.7*10
20
 
MID Not 
estimated 
0.08 0.03 0.05 0.05 0.03 
1
Hawthorne et al, 1999; 
2
 Walters and Brazier, 2005, 
3
 Sintonen, 1994, Sintonen 1995; 
4
Horman et al, 2003;
 5
 Ware, 
2000; 
6
The questionnaire used is SF-36 
 
The HRQoL instruments shown in Table 1 were developed across diverse periods. The 
tendency has been such that the use of an instrument has been most common in the country in which it was 
developed (Richardson et al., 2012). Currently, the EQ-5D appears to be the most widely used instrument 
worldwide (Räsänen, 2006). In addition, as mentioned earlier, the 2002 Brussels Roundtable Consensus 
Meeting recommended the EQ-5D (and the SF-36) as the preferred HRQoL instruments in the critical care 
setting. Therefore, it seemed appropriate to more closely examine the EQ-5D and to compare it in the critical 
care setting to the 15D, which is the most frequently used utility instrument in Finland.   
19 
 
2.1.1 The EQ-5D 
 
The EQ-5D was developed by an international research group, named the EuroQol Group. 
The EuroQol Group was established in 1987 and included members from Finland, Netherlands, Norway, 
Sweden and the United Kingdom (Rabin and de Charro, 2001). The original goal of the EuroQol Group was 
to develop a very simple health state descriptive system, to generate from it a small number of different 
health states to be valued in a standardised way in a representative population sample in different countries 
and to determine whether the valuations across countries are similar to one another. The instrument was not 
intended to be used as a stand-alone measure, but to complement other forms of quality-of-life measurement 
tools and to facilitate the collection of a common dataset for reference purposes (Brooks, 1996). 
 
The health state descriptive system 
The health state descriptive system of the EQ-5D was developed through a conceptual process 
on the basis of the available HRQoL instruments. Altogether, seven different HRQoL instruments were 
reviewed during the development process. Of these instruments, the Quality of Well-Being Scale, the Rosser 
Index and the 15D represented both generic and profile instruments (Coast, 1992; Coons et al., 2000; 
Sintonen, 2001), while the Sickness Impact Profile, the Nottingham Health Profile and the Health 
Measurement Questionnaire were simply profile instruments (Cole et al., 1994; Coons et al., 2000). The 
members of the EuroQol Group presupposed that the forthcoming instrument should include dimensions 
related to mobility, daily activities, self-care, psychological functioning, social and role performance and 
pain or other health problems (EQ-5D concepts and methods, 2005). 
The prerequisites for development were that the chosen dimensions should be wide in content 
and suitable for different health states, and that the instrument should be usable by the general population in 
different health states. The first version consisted of six dimensions (6D) with two to three levels on each 
dimension. The six dimensions were mobility, self-care, main activity, social relationship, pain and mood. 
The levels of the dimensions were on an ordinal scale except for the dimension of self-care, which was on a 
nominal scale. The levels on the dimension of self-care were no problems in self-care, unable to dress 
independently and unable to eat independently. On the basis of experiences and experiments, a new version 
was ratified in 1991. It consists of five dimensions: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. The dimension social relationship was excluded. The revision focused on levels as well; 
all dimensions were changed to ordinal and included three levels: no problems, some or moderate problems 
and unable or extreme problems. The EQ-5D instrument can generate 243 different health states. The 
number of different health states was limited in order to enable the use of a holistic valuation method (The 
EuroQol Group, 1990; Brooks et al., 1996).  
The basic idea behind the EuroQol Group was to develop a very simple health state 
descriptive system, to derive from it a small, standardised set of different health states, to value them in a 
standardised, holistic way in a representative population sample in different countries and to see whether the 
valuations are similar or different across countries. The EQ-5D was never intended to be a stand-alone 
instrument; but, rather, was meant to complement other HRQoL measures (EuroQol Group, 1990; Brooks et 
al., 1996; Sintonen et al. 2003). 
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The valuation methods 
 
Primarily, two different valuation methods have been used to generate a single-index score for 
the health states defined by the EQ-5D descriptive system. These methods are the Visual Analogue Scale 
(VAS) and the Time Trade-Off method (TTO) (Greiner et al., 2003; Rabin and de Charro, 2001). The VAS 
method consists of a line with two clearly defined end points (Green et al., 2000). In the EQ-5D VAS 
valuation system, the end points are the best imaginable (100) and the worst imaginable (0) health state 
(Brooks et al., 1996; Greiner et al., 2003). In the VAS valuation process, respondents draw a line from boxes 
describing different, earlier defined health states on the scale (“thermometer”) to indicate how good or bad 
they are. In the TTO method, the respondents choose between two alternatives: x years in full health or a 
previously defined number of years (e.g., 10) in the health state being valued i.e., how much of the lifetime 
the respondent is willing to sacrifice in order to achieve a higher quality of life (Dolan, 1997; Green et al., 
2000). Comparing these two valuation methods, the TTO produced higher utility weights in mild and 
moderate health states and considerably lower utility weights in severe health states (Brazier et. al., 1999). In 
QALY calculations and cost-utility analyses, it has been recommended that the EQ-5D scores defined by the 
TTO method should be used (Rabin and de Charro, 2001). 
Using the TTO method, 43 of the 243 possible health states were valued by 3 337 respondents. 
Each respondent valued 11 different health states varying from very mild to severe health states. In addition 
to perfect health (11111), worst possible health state (33333), immediate death and unconsciousness (not 
defined) were valued.  The respondents represented the general population of the United Kingdom. The 
respondents completed the health states valuation differently for health states considered better and worse 
than death. In the former case, the respondent chose between 10 years in the health state being valued to be 
equivalent to a length of time (x) in perfect health. In the latter case, the respondent chose between dying 
immediately and a length of time (x) in the health state being valued following 10 – x years in perfect health 
(Dolan et al., 1996).  
These 43 health states were used to create a regression model to interpolate an index score for 
the rest ofhealth states. In the regression model, the constant for any dysfunctional state is -0.081, i.e., when a 
level of some or moderate problems occurs on any of the dimensions. In addition to the constant, the final 
score consists of the reduced value of the level from each dimension. As a consequence, no health state can 
obtain a value between 0.888 and 0.999. In addition, the regression model includes a dummy variable (N3) 
which means that, if any of the dimensions is at level three, -0.269 is subtracted from the score (Dolan, 
1997).  
These reductions will cause substantial changes in the single-index scores when one moves 
from one level to another. Pain has the most significant effect on the utility score—if pain is at level 3 and all 
other dimensions are at level 1, the single-index score is 0.264. The final score is produced through addition. 
The scale of the index score is -0.594 – 1, where 1 indicates full health and 0 represents death. Altogether, 84 
health states—i.e., 35% of all possible health states—are WTD (Walters and Brazier, 2005). The above 
applies to the UK TTO tariff. The EQ-5D tariff varies between countries — e.g., in the United States, the 
lowest utility score in the original D1 tariff is -0.102, while in Spain, the lowest is -0.654 (Heijink et al., 
2011). All of these tariffs have been based on mean TTO valuations. However, in the United States, a new 
tariff based on median TTO valuations (MM–OC model) is now recommended for use. In this tariff, the 
scores range from -0.81 to 1 (Shaw et al., 2010). 
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The minimal clinically important difference 
 
The EuroQol Group has not estimated MID for the EQ-5D, so there is no commonly accepted 
value for MID. The MID estimation was initiated by researchers in the 2000s. Using previously published 
studies, Walters and Brazier investigated MID derived from both the anchor- and the distribution-based 
methods for 11 different patient groups. Depending on the patient group, the anchor-based MID varied from 
-0.011 to 0.139 and the distribution-based MID ranged from 0.11 to 0.17. For the entire patient population, 
the mean MID was 0.074 and the median MID 0.081 when estimated using the anchor-based method 
(Walters and Brazier, 2005). In addition, MID has been estimated at 0.08 using distribution- and anchor-
based methods in cancer patients (Pickard et al., 2007), from 0.08 to 0.10 using the anchor-based method in 
multiple myeloma patients (Kvam et al., 2011) and at 0.05 using the distribution-based method in 
rheumatoid arthritis patients (Marra et al., 2005).  
In 2011, the EuroQol Group introduced a new version of the EQ-5D instrument. The 
differences between the old and new versions lie in the number of levels for each dimension as well as some 
changes in the wording of previous levels. The number of levels has been increased from three to five, which 
includes no problems, slight problems, moderate problems, severe problems and extreme problems. The 
name of the EQ-5D instrument has also been further refined, whereby the three-level version is called the 
EQ-5D-3L and the five-level version is known as the EQ-5D-5L. It is possible to use a link between the EQ-
5D-5L and EQ-5D-3L descriptive systems to create an index score for the EQ-5D-5L health states (EuroQol 
Group, 2011). Until the new valuation system for the EQ-5D-5L is completed, which combines discrete-
choice experiment (DCE) and TTO methods, the instrument should be regarded as a profile instrument since 
the resulting scores yield the EQ-5D-3L scores. Because of the changes in the health state descriptive system 
(new levels and partly new wording from the previous version) and the new valuations method, the EQ-5D-
5L is in fact a new instrument and comparability with results obtained using the EQ-5D-3L are most likely 
lost.  
 
2.1.2 The 15D 
 
The development of what is now known as the 15D started in the late 1970s. The original 
target was to develop a comprehensive HRQoL instrument which could be used both as a profile and generic 
instrument (Sintonen 1994; Sintonen, 2001). 
The health state descriptive system 
The first version of the 15D was called the 12D and included 12 dimensions with 4–5 levels 
on each dimension. The conceptual basis for the health state descriptive system relied on the definition of 
health by WHO (WHO, 1958). In addition, the 12D was based on dimensions of health considered important 
in contemporary Finnish health policy documents. 
According to feedback from the medical profession, the instrument was too concentrated on 
physical well-being. Thus, a new version was launched in 1986 and included additional dimensions 
concerning mental health including depression, distress and pain. This revised instrument was named the 
15D.1. The suitability of the 15D.1 regarding its ability to reflect HRQoL was tested among nearly 3 000 
individuals. The intention was to determine whether the instrument had too many attributes or if something 
essential was missing. After revisions based on these initial results and statistical analyses, an updated 
version (the 15D.2) was launched in 1992. In the 15D.2, the ability to work and social participation were 
combined into one dimension, labeled “usual activities” and a new dimension on sexual activity was added. 
In addition, all dimensions were changed to five-level scales in order to increase sensitivity. What is today 
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referred to as the 15D is actually the 15D.2 and the dimensions are mobility, vision, hearing, breathing, 
sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, 
distress, vitality and sexual activity. The instrument can generate 30.5 billion different health states 
(Sintonen, 1994; Sintonen, 2001). 
 
The valuation system 
Due to the large number of different health states, it is not possible to use direct and holistic 
valuation methods (Honkalampi and Sintonen, 2010). The health states values are produced indirectly by 
applying multi-attribute utility theory. The valuation process comprised three stages and was performed on a 
representative sample of the Finnish adult population. During the first stage, relative importance weights 
were elicited from the top levels of the 15 dimensions. At the second stage, importance weights were elicited 
from the lowest levels (5) of the dimensions. The valuation procedure was completed using a 0–100 ratio 
scale (VAS scale), where 100 was given to the most important dimension, and 0, was assigned if a dimension 
was not considered important at all. The ratio scale nature of the valuation task was emphasized by placing nine 
arrows to the right-hand side of the 0–100 scale with a text explaining how the number pointing to an arrow 
should be interpreted over the range of the scale. For example, an arrow pointing to 90 reads, “9/10 as important 
as the most important attribute (90% as important as the most important attribute).” The importance weights for 
the intermediate levels were extrapolated linearly from the weights of the extreme ends in relation to the distance 
between level values, which were elicited for each dimension during the third stage. In addition to the five 
levels, the states “unconscious” and “dead” were valued on for every dimension. The preference weight for 
each level was calculated by multiplying the level weight by the importance weight for the dimension. The 
most important dimensions for good HRQoL are mental function (i.e., to be able to think clearly and 
logically), to be able to breathe normally and, to be able to perform usual activities (such as work, leisure and 
hobbies) normally.  
The total score over all dimensions through the 3-stage additive valuation procedure is obtained as follows: 
 , 
where Ij(xj) is the average relative importance people attach to various levels of dimension j (j = 1, 2,..,15) 
and wj(xj) is the average value people place on various levels of dimension j. 
The scale for the single-index score is 0–1, where 1 indicates full health, 0.0162 represents 
unconsciousness and 0 represents death (Sintonen, 1995). 
In a recent study, the 15D scores were compared to the TTO valuation of one’s own health 
among 863 patients representing various levels of severity in different disease groups. At the aggregate level, 
the 15D and TTO scores had good agreement, although in some patient groups the agreement was not that 
good (Honkalampi and Sintonen, 2010). 
 
The minimal clinically important difference 
 
MID has been estimated by the developer of the instrument using an anchor-based method 
among 1 231 patients. The anchor was the patient’s experience concerning his or her health state compared 
to 6 months earlier. MID was reported to be 0.03 (Sintonen, 1994). Recently, MID was re-evaluated and 0.03 
was considered a suitable clinically important magnitude of change in the case the magnitude should be 
equal to both directions. In relation to a positive change (i.e., improvement to HRQoL), it is possible that an 
even smaller change in the range of 0.02 could be experienced by patients as important. On the other hand, 
)]()[( jjjjH xwxIv 
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0.03 may be too small a magnitude of change when HRQoL deteriorates when a negative value for MID 
should reach 0.05 (Alanne, 2011). 
 
2.1.3 Comparison of the EQ-5D and the 15D in different patient populations 
 
The comparison of results using different utility instruments began as early as the end of the 
1990s, intensifying during the 2000s. The instruments can be compared in terms of several properties, where 
sensitivity may be one of the most important properties.  
The sensitivity of an instrument entails two aspects. The first aspect concerns its ability to 
distinguish between individuals and groups in different health states cross-sectionally (discriminatory 
power). Second, instruments are evaluated based on their ability to detect changes in individuals or groups 
over time (responsiveness to a change in one’s health status). In addition, different criteria can be used for 
evaluating an instrument’s discriminatory power. First, this refers to the ability of the instrument to detect 
health problems which can be described by a number of different health states. Second, the discriminatory 
power refers to the ability of the instrument to detect changes in health. This can be described by the ceiling 
and floor effects. Furthermore, the properties of the distribution of the scores—e.g., skewness and 
peakedness—can tell researchers something about the discriminatory power (Sintonen, 1994).  
The “ceiling” and “floor” effect and skewness can also be used to describe the instrument’s 
responsiveness to change. In addition, responsiveness indices such as ES and SRM have been used. ES is 
defined as the change in the mean score from the baseline to follow-up divided by the standard deviation at 
the baseline measurement. SMR is the mean response divided by the standard deviation of responses, which 
equals the paired t-statistic without factoring in the sample size (Liang et al., 1990). 
The EQ-5D and the 15D have been compared among patients groups in relation to diseases 
such as chronic obstructive pulmonary disease, epilepsy, rheumatoid arthritis, cancer, type II diabetes, HIV 
and rehabilitation patients with musculoskeletal, cardiovascular or psychosomatic disorders. Most of these 
studies have focused on outpatients (Stavem, 1999; Stavem et al., 2001; Linde et al., 2008; Stavem et al., 
2005; Moock and Kohlmann, 2008; Kvam et al., 2011; Lillegraven et al., 2010; Kontodimopoulos et al., 
2012). In addition to patient groups treated in ambulatory settings, the EQ-5D and the 15D have been used in 
comparisons of patients requiring inpatient care and in residents of a community (Hawthorne et al., 2001; 
Saarni et al., 2006; Saarni et al., 2010).  
In general, the mean utility scores have been higher for the 15D than for the EQ-5D with the 
differences tending to be larger when the utility values are low. The difference in utility scores between 
instruments varies from 0.07 to at least 0.22. The EQ-5D has a tendency to a ceiling effect, i.e., showing a 
considerable concentration of scores at the maximum end of the scale (i.e., 1). The ceiling effect has varied 
from 10% in multiple myeloma patients to 42% in patients with epilepsy. In corresponding patient groups, a 
score of 1 was obtained by 0% and 14% of patients, respectively, when using the 15D (Stavem, 1999; 
Hawthorne et al., 2001; Stavem et al., 2001; Linde et al., 2008; Stavem et al., 2005; Saarni et al., 2006; 
Moock and Kohlmann, 2008; Saarni et al., 2010; Kvam et al., 2011; Lillegraven et al., 2012; 
Kontodimopoulos et al., 2012) (Table 2).   
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Table 2. Descriptive statistics of the utility scores using the EQ-5D and the 15D in different patient 
populations 
 Mean utility 
score 
Range Ceiling effect (%) 
Patient group EQ-5D 15D EQ-5D 15D EQ-5D 15D 
Epilepsy
1
 0.81 0.88 -0.11-1.00 0.39-1.00 42.0 14.0 
HIV/AIDS
2
 0.77 0.86 -0.33-1.00 0.43-1.00 29.0 10.0 
Cancer
3
 0.74 0.86 --- --- 29.0 7.0 
Diabetes
3
 0.67 0.83 --- --- 21.0 6.0 
Heart failure
3
 0.59 0.77 --- --- 8.0 1.0 
Cardiovascular
4,5
 0.73 0.86 -0.07-1.00 0.56-1.00 21.6 5.7 
Cardiovascular
6,5
 0.76 0.88 -0.07-1.00 0.55-1.00 26.1 10.2 
Muskuloskeletal
4,5
 0.63 0.84 -0.18 -1.00 0.60-1.00 5.7 1.9 
Muskuloskeletal
6,5
 0.67 0.87 -0.08-1.00 0.64-1.00 7.5 4.7 
Psychosomatic
4,5
 0.57 0.76 -0.08-1.00 0.52-0.94 4.2 0 
Psychosomatic
6,5
 0.57 0.79 -0.14-1.00 0.46-1.00 4.3 1.4 
1
Stavem et al., 2001,
 2
Stavem et al, 2005, 
3 
Saarni et al., 2006, 
4 
Baseline HRQoL,  
5 
Moock and Kohlman, 2008, 
6
Follow-up HRQoL. 
Among these relatively healthy patient populations, the EQ-5D produced HRQoL scores < 0, 
suggesting health states WTD. The percentage of patients scoring WTD has not been systematically 
reported, but the proportion of patients has varied from 3% to more than 6% (Moock and Kohlmann, 2008; 
Lillegraven et al., 2012). For these patients, the 15D score is positive, i.e., the 15D does not produce negative 
values. 
The 15D has been shown to be more sensitive in detecting change in HRQoL and in 
discriminating different health states than the EQ-5D (Stavem, 1999; Moock and Kohlman, 2008; Saarni et 
al., 2010; Kontodimopoulos et al., 2012). This might be due to the notable ceiling effect of the EQ-5D. 
Furthermore, the richer health state descriptive system of the 15D may play a role. However, different results 
have also been reported. For example, in HIV patients, the responsiveness according to the clinical state did 
not differ between instruments, although the 15D showed a higher responsiveness to improvement (Stavem 
et al., 2005). In multiple myeloma and rheumatoid arthritis patients, the 15D did not detect a statistically 
significant change in the group of deteriorating patients, although the mean changes were negative (Linde et 
al., 2008; Kvam et al., 2011). In general, the quantity of the change in the HRQoL score is larger in the EQ-
5D compared to the 15D (Stavem et al., 2001; Kvam et al., 2011). 
 
2.2 Quality-adjusted life years 
 
As mentioned above, a widely used approach for quantifying health gains is to use QALYs 
gained as a measure of the effectiveness of care. QALY combines two main outcomes of health care: 
mortality and morbidity, while also highlighting the populations’ preferences (Bleichrodt and Johannesson, 
1996). QALYs allow for comparisons between different patient populations and health-care interventions 
using a single, universal indicator (Prieto and Sacristan, 2003; Dolan et al., 2005; Brauer et al., 2006).   
The foundation of QALY lies in utilitarian philosophy — people wish to maximise benefits 
and minimise harm (Dolan, 2001). An essential factor in the QALY model is the utility weight. The utility 
weight indicates the trade-off between the quality and the length of life (Scuffham et al., 2008). This trade-
off means that individuals enjoying full health are unwilling to sacrifice any length of life; but, for 
individuals in, for example, a health state with a utility weight of 0.5, they are willing to sacrifice 50% of 
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their expected lifetime to become perfectly healthy for the rest of their lifetime. This implies that, for young 
people, low utility values mean greater losses than for older individuals. The utility weights lie along an 
interval scale; the same magnitude of change is equally valued across the entire scale (0–1). Thus, a change 
from 0.3 to 0.4 is as valuable as a change from 0.9 to 1 (Whitehead and Ali, 2010). 
Although QALY is a widely accepted indicator to measure health gains, it has also been 
criticised. When applying TTO to the valuations of health states, one problem can be found in patients’ 
reluctance to trade off lifetime (Nord et al., 2009). For example, when patients with advanced cancer valued 
their own health status using TTO, some respondents irrespective of their health state refused to trade off any 
lifetime. As a consequence, the utility index can be 1 (i.e., perfect health) even for patients with 
symptomatic, metastatic cancer (Perez et al., 2003). This problem might be overcome by using a generic, 
single-index HRQoL instrument which accounts for the symptoms experienced by the patient.  
Another concern is the fairness of the maximisation of QALYs. Maximisation implies that 
health-care interventions should be focused on patients with the largest potential to benefit, while society 
may prefer to focus on patients who are worse off (National Centre for Priority Setting in Health Care 2008; 
Nord et al., 2009). However, the calculation of QALYs does not automatically imply the maximisation of 
QALYs and the principle for the allocation of health-care resources and prioritising treatments and patients 
may be different from the QALY maximisation. 
In addition to the recommended generic HRQoL instruments, utility weights have been 
produced using holistic valuation methods and by mapping disease-specific measures to generic HRQoL 
instruments (Brauer et al., 2006; Marra et al., 2007; Kontodimopoulos et al., 2009). In addition, a utility 
catalogue exists which includes 2 159 different utility weights collated from previously published studies. 
However, utility weights are not available for all diseases and different utility weights for the same health 
states can be found depending upon which HRQoL instrument and valuation method was used. For example, 
the utility weights in myocardial infarction vary from 0.58 to 0.93 (Brauer et al., 2006).  
 
2.2.1 The calculation of QALYs 
 
Regardless of the criticism related to some aspects of QALYs, they are still considered a 
useful method for evaluating the effectiveness of different health-care interventions. Indeed, the United 
Kingdom’s National Institute for Health and Care Excellence (NICE) regards QALYs gained as its principal 
measure of the outcome of care (Rawlins and Culyer 2004). The quantification of QALYs requires a 
decision about the duration of the benefit of care (time horizon of the calculation), the manner in which 
HRQoL changes during the time horizon and whether one is calculating the number of QALYs experienced 
or QALYs gained. At present, there is no consensus on how to tackle these issues.  
To begin with, what is the most appropriate time horizon—i.e., the duration of the benefit of 
care—to be used in QALY calculations? For instance, guidelines from NICE advise calculating QALYs for 
an appropriate time horizon (Guide to the Methods of Technology Appraisal, 2008). The Finnish guidelines 
for the evaluation of medicines issued by the Pharmaceuticals Pricing Board of the Ministry of Social Affairs 
and Health state that the time period should be long enough to take into account all essential costs and health 
effects (Pharmaceuticals Pricing Board, 2011). As a consequence, diverse time horizons have been used 
varying from short time periods to tens of years. Some examples of time horizons include the follow-up time 
(Cuthbertson et. al., 2010; Kantola et al., 2010; Harris et al., 2011; Sultan and Hynes, 2011), life expectancy 
(Sznajder et al., 2001; Linko et al., 2010; Peek et al., 2010) and reduced life expectancy (Talmor et al., 2008; 
Mahonay et al., 2011; Malmivaara et al., 2011). 
Due to the fact that the frequent measurement of HRQoL (e.g., on a daily basis) is normally 
not possible, attention should be paid to the manner in which HRQoL changes during the time horizon used 
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for analysis (Manca et al., 2005). Three different assumptions have been proposed: HRQoL changes linearly 
between measurement points; HRQoL remains constant from one measurement to the next and then changes 
overnight; and HRQoL changes at the midpoint between measurements (Billingham et al., 1999). In 
addition, a fourth assumption has been used within the critical care setting, namely, that the change in 
HRQoL takes place at the start of care (Karlsson et al., 2009).  
When discussing QALYs, one must make the clear distinction between QALYs experienced 
and QALYs gained. This difference is illustrated using imaginary data as shown in Figure 2. Here, HRQoL 
has been measured at 1-year intervals in a hypothetical patient group without treatment. The resulting mean 
HRQoL scores (utility values) are shown on the vertical axis. HRQoL is assumed to change linearly between 
the measurement points and results in a curve. The entire area under the curve (AUC, the grey area) 
calculated using the trapezium rule represents the mean number of QALYs experienced by the patient group 
during the time horizon of four years, i.e., during their remaining life expectancy. 
Had the patient group been treated, it would have experienced higher mean HRQoL scores 
and lived longer. Here, The AUC (grey and black areas) represents the mean number of QALYs experienced 
and the black area represents the mean number of QALYs gained by the patient group receiving treatment.  
 
 
 
 
Figure 2. QALYs experienced and QALYs gained 
 
When calculating QALYs, one should pay attention to the baseline utility value since it is 
strongly correlated with the number of QALYs (Manca et al., 2005). In circumstances where the baseline 
utility weight is unknown and it is challenging to obtain it such as in critical care setting, assumptions about 
the baseline utility weight must be made.  
Although the calculation of QALYs includes several elements, in many cases the calculation 
methods are not explained transparently (Richardson and Manca, 2004; Schwappach and Boluarte, 2007; 
Rodriguez et al., 2011). In addition, the utility weights and the change in them are expressed as mean values 
and the dispersion of QALYs experienced or gained are not reported. 
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2.3 Critical care 
 
Critical care is delivered in special units called intensive care units (ICU) or high-dependency 
units (HDU). The most serious conditions are treated and the most demanding forms of care are provided in 
ICU. Critical care is resource-intensive; medical staff is available around the clock and nurses can take care 
of only one to three patients at a time depending on the patients’ states. In addition to the heavy personnel 
burdens, the critical care environment is technologically advanced featuring diverse equipment to monitor 
patients and to deliver demanding care such as mechanical ventilation and renal replacement therapy 
(Valentin and Ferdinande, 2011). From the patients’ point of view, the critical care environment is stressful 
(Almerud et al., 2007). Typically, critical care patients are confined to bed, connected to monitoring devices 
via cables and are unable to express themselves. In addition to the physical discomfort, serious illnesses raise 
the fear of the discontinuance of life (Wang et al., 2008).  
Although there is no rule regarding upon which patients ICU treatment should be focused, it is 
generally accepted that it should be focused on patients with reversible medical conditions with a high but 
not enormous risk of death (Task Force of the American College of Critical Care Medicine, 1999). In 
addition, it has been stated that admission to critical care requires that a patient’s vital functions are 
threatened by an acute disease event, by surgical or other intensive treatment or when one or more of the 
vital functions have already failed and the patient needs demanding interventions. In addition to the life 
threatening condition, the patient should have the potential for recovery (Valentin and Ferdinande, 2011). 
The typical surgical treatments requiring critical care are, inter alia, cardiac surgery, neurosurgery and many 
arterial surgical procedures. Typical medical illnesses requiring critical care are acute myocardial infarction, 
cardiac arrest, respiratory failure, sepsis and neurological diseases such as stroke or cerebral haemorrhage 
(Mayer et al., 2000; Graf et al., 2005; Seferian and Afessa, 2006; Graf et al., 2008). 
 
2.3.1 Critical care patients’ survival 
 
Although only patients with the potential to recover should be referred to critical care, the 
mortality rate among critical care patients is high at least within the first year after the initiation of treatment 
(Kaarlola et al., 2003; Rimachi et al., 2007; Karlsson et al., 2009; Linko et al., 2010; Khouli et al., 2011). 
Among general ICU patients, mortality has been reported to vary from 16% to 44% (Rotondi et al., 2002; 
Deja et al., 2006; Merlani et al., 2007; Cuthbertson et al., 2010) and hospital mortality from 24% to 58% 
(Graf et al., 2008; Khouli et al., 2011; Vaara et al., 2012) depending on the diagnostic category. For example, 
the 1-year mortality of sepsis patients was reported to be 41% (Karlsson et al., 2009), 46% for acute heart 
failure patients (Zannad et al., 2006) and 34% for patients with infections (Mayr et al., 2006). 
The mortality rate is lower in ICU patients receiving elective surgery compared with 
emergency admissions (Niskanen et al., 1996). For instance, in cardiac surgery patients, the 6-month 
mortality has been reported to vary from 2% to 6% (Welsby et al., 2002; Schelling et al., 2003; Hein et al., 
2006; Pätilä et al., 2006; Van den Heede et al., 2009). Long ICU stays predict higher mortality rates among 
cardiac surgery patients. Hospital mortality has been reported to vary from 8.5% to 52.9% after a prolonged 
ICU stay (Pappalardo et al., 2004; Gersbach et al., 2006; Hein et al., 2006; Gaudino et al., 2007).   
In addition, long-term mortality is high among critically ill patients. For acute respiratory 
distress syndrome patients discharged alive from ICU, the 2-year mortality was 49%, while for general ICU 
patients alive 6 months after treatment at ICU, the 9-year mortality was 44% (Cheung et al., 2006; Stricker et 
al., 2011). For general ICU patients, the 2-year mortality including ICU mortality was 53% (Schenk et al., 
2012), while for surgical ICU patients, the 6-year mortality was 54% (Timmers et al., 2011). For cardiac 
surgery patients, mortality varied according to the length of stay in ICU. In the group with a short ICU stay 
28 
 
(i.e., 3 days or less), the mortality rate during a 3-year follow-up was 9% compared to 34% in the group of 
long ICU stay patients (Hein et al., 2006). After an isolated aortic valve replacement (AVR) procedure, 
mortality during a 5-year follow-up was 11.4% for patients younger than 80 years and 28.1% for those 80 
years or older (Saxena et al., 2012). 
 
2.3.2 The costs of critical care 
 
There are two notable issues to take into account in determining patient-specific costs. First, 
the cost per patient usually varies significantly, and second, the costs of treatment for a single patient can 
reach tens of thousands or even hundreds of thousands of Euros. For example, the costs per cardiac arrest 
patient were reported to vary from 1 708 € to 181 500 € (Graf et al., 2008), while those for general ICU 
patients ranged from 1 474 USD to 261 051 USD (Wachter et al., 1995). Low ICU costs usually indicate 
either a fast recovery or a fast death. For critical care patients, ICU costs and total hospital costs mostly 
depend on the length of the ICU stay (Graf et al., 2008; Niskanen et al, 2009; Linko et al., 2010).  
The average total hospital costs for critical care patients have usually been reported to be on 
the order of 20 000 – 50 000 USD regardless of the reason for care, i.e., scheduled surgery or acute care. The 
tendency is that the care is more expensive in older patients (Agarwal et al., 2010; Gelsomino et al., 2011) 
and that patients at the highest risk are not necessarily the most expensive (Hamel et al., 2000). However, 
attention must be paid to the fact that the calculation and source of costs are not congruent across all studies 
(Table 3). 
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Table 3. Total hospital costs for cardiac surgery and general ICU patients in various studies (costs in USD 
unless otherwise stated)  
Study Patient group (N) Mean costs (SD) Median (Q1/Q3) Cost source 
Hamel et al., 
2000 
ARDS6 
Low-risk (292) 
Medium-risk (385) 
High-risk (286) 
 
59 096 (64 336) 
70 130 (85 300) 
59 310 (54 590) 
 Based on billing 
Moran et al., 
2004 
ICU patients (1 333) 9 3438 ( - )  South Australian Health 
Commission Study 
Dasta et al., 
2005 
Mechanical ventilation 
(18 590) 
Non-mechanical 
ventilation (32 419) 
47 158 (57 703) 
 
23 707 (34 545) 
 Based on billing 
Graf et al., 
2005 
Medical ICU patients 
(190 ) 
14 1306 (-)  Patient-specific (variable) 
and non-patient-specific 
(fixed) costs  
Cheung et al., 
2006 
ARDS (78) 128 8607 (-)  Hospital Administrative 
Database 
Karlsson et al., 
2009 
Sepsis (269) 32 5635(-)  Estimated from total 
annual costs 
Agarwal et al., 
2010 
CABG1 
40-50 years (149) 
50 – 60 years (605) 
60-70 years (1006) 
70-80 years (754) 
≥ 80 years (268) 
 
27 580 (12 465) 
30 904 (17 765) 
33 758 (25 896) 
37 426 (31 455) 
42 115 (29 729) 
 Maryland Health Services 
Cost Review Commission 
Bhamidipati et 
al., 2011 
CABG1 (1992) 
AVR2 (352) 
MVR3 (81) 
CABG+valve4 (654) 
35 017 (31 540) 
37 759 (23 581) 
47 274 (31 440) 
44 965 (30 003) 
 Virginia Cardiac Surgery 
Quality Initiative Registry 
Gelsomino et 
al., 2011 
(70–79 years   n 1230   
     ≥ 80 years  n 1640) 
CABG1  
70 – 79 years 
≥ 80 years 
AVR2    
70 – 79 years 
≥ 80 years 
MVR3 
70 – 79 years 
≥ 80 years                
CABG+valve4   
70 – 79 years 
≥ 80 years 
 
  
 
 
12 212   (6 120/18 220) 
16 759 (13 696/28 612) 
 
14 431   (6 512/19 436) 
19 760 (11 340/30 100) 
 
16 019   (8 440/23 619) 
21 307 (12 430/34 215) 
 
16 650   (8 979/24 011) 
22 666 (12 496/34 620) 
Hospital and outpatient 
financial registers  
Robinson, 2011 Cardiac valve 
replacement (37 hospitals) 
43 733 (14 794) 
 
 Hospital finance 
department 
Cohen et al., 
2012 
CABG1 (870) 33 254 (9 782)  IMS Hospital Supply 
Index, statistical 
estimation 
Iribarne et al., 
2012 
MVR (105)   ≥ 75 years 60 289 (4 843)  Hospital finance 
department 
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1
Coronary Artery Bypass Graft Surgery, 
2
Aortic valve replacement, 
3
Mitral valve replacement 
4
Combined Coronary Artery Bypass Graft and valve Surgery, 
5€, 6Acute respiratory distress syndrome, 
7
Canadian $,
8
Australian$ 
 
2.3.3 HRQoL measurement in critical care patients 
 
The HRQoL instruments most often used among acutely ill critical care patients include the SF-36 
profile instrument and the EQ-5D. The 15D has also been used in a few studies (Elliot et al., 2004; Kantola 
et al., 2010). Due to the challenges in establishing baseline HRQoL in acutely ill critical care patients, 
various approaches have been used to calculate QALYs: 
  Follow-up HRQoL has been compared to that for the general population (Kvale et Flaatten, 2003; 
Stricker et al., 2005; Deja et al., 2006; Ringdal et al., 2009; Linko et al., 2010; Orwelius et al., 2010; 
Timmers et al., 2011).  
 The baseline HRQoL has been considered the value of 0 assuming that, without treatment, patients 
would die (Graf et al., 2005; Linko et al., 2010; Peek et al., 2010).  
 The prevailing HRQoL value before treatment has been assessed using proxies (Badia et al., 2001; 
Wehler et al., 2003; Merlani et al., 2007; Hofhuis1 et al., 2008; Hofhuis2 et al., 2008; Cuthbertson et 
al., 2010; Vaara et al., 2012) or by professionals (Kantola et al., 2010).  
Studies comparing follow-up HRQoL among surviving patients to that for the population have 
usually found it to be impaired (Deja et al., 2006; Merlani et al., 2007; Karlsson et al., 2009; Cuthbertson et 
al., 2010; Linko et al., 2010). For example, the mean EQ-5D score 12 months after ICU treatment was 0.67 
compared with the population’s score of 0.82 (Cuthbertson et al., 2010). When the follow-up HRQoL was 
compared to the proxy-assessed baseline HRQoL measured using the EQ-5D, the median follow-up HRQoL 
was worse than the proxy-assessed baseline HRQoL in renal replacement therapy (RRT) patients (0.63 vs. 
0.68) and similar in patients who did not need RRT (0.68 vs. 0.69) (Vaara et al., 2012). However, when the 
comparison was made to the HRQoL prevailing at the start of care, the follow-up HRQoL was clearly higher 
(0.30 vs. 0.70) in acute liver failure patients measured using the 15D (Kantola et al., 2010). 
Furthermore, in cardiac surgery patients, the most commonly used HRQoL instrument has 
been the SF-36 profile instrument; however, in contrast to acutely ill critical care patients, the baseline 
HRQoL has been assessed by the patients themselves. The target has been to establish the HRQoL prevailing 
before treatment and, then, to compare it to the follow-up HRQoL after treatment (Schelling et al., 2003; 
Hawkes and Mortensen, 2006; Jokinen et al., 2010; Grady et al., 2011). The mean follow-up HRQoL scores 
after cardiac surgery have been found to significantly improve compared to the baseline HRQoL scores 
(Hawkes and Mortensen, 2006; Azzopardi and Lee, 2009; Loponen et al., 2009; Gjeilo et al., 2012; Markou 
et al., 2011). For example, the mean baseline HRQoL score measured using the EQ-5D in coronary artery 
bypass graft surgical (CABG) patients was 0.68 and 0.67 in AVR patients. At follow-up 12 months after 
treatment, the mean HRQoL scores were 0.78 and 0.71, respectively (Markou et al., 2011). Using the 15D, 
the mean baseline HRQoL score in CABG patients was 0.75 (Kattainen, 2004) and 0.83 (Loponen et al., 
2009) and the follow-up score 6 months after treatment of 0.86 (Kattainen 2004, Loponen et al., 2009). 
Compared with the general population, mean HRQoL for cardiac surgery patients was reported to be fairly 
good (Gjeilo et al., 2006). However, although cardiac surgery patients on average benefit from the surgical 
procedure, 9% to 27% of patients experience a deterioration in their HRQoL score (Gersbach et al., 2006; 
Hawkes and Mortensen, 2006; Trouillet et al., 2011).   
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The reasons for these low and divergent follow-up HRQoL scores in some patients have been 
contemplated. The deterioration of HRQoL has not been associated with age, mortality risk, gender, duration 
of mechanical ventilation, sedation or length of ICU stay (Graf et al., 2005; Stricker et al., 2005; Deja et al., 
2006; Gersbach et al., 2006; Hofhuis1 et al., 2008; Davydow et al., 2009; Vest et al., 2011). By contrast, 
psychotic experiences, delusional memories, delirium and anxiety experienced during an ICU stay have been 
reported to affect follow-up HRQoL in a negative manner (Deja et al., 2006; Davydow et al., 2009; Loponen 
et al., 2008; Ringdal et al., 2009).  
 
2.3.4 QALY calculation in the critical care setting 
 
In principle, the measurement of QALYs is quite relevant in the critical care setting given that 
the goal of care is both to lengthen life and improve HRQoL in spite of the fact that the rule of rescue—that 
is, the duty to save an endangered life where a possible benefit can occur—applies. However, the methods 
used in QALY calculations vary between studies. For example, in some studies the cost per QALY gained 
has been calculated without using data based on a generic HRQoL instrument, although such data are an 
essential component of QALY calculations (Wu et al., 2007; Al-Ruzzeh et al. 2008; Graf et al., 2008; 
Yaghoubi et al., 2011; Gelsomini et al., 2011). Furthermore, the measurement of HRQoL has been reported 
in an incoherent way (Wu et al., 2007) and the population’s age- and sex-matched HRQoL scores have been 
used among non-respondents (Linko et al., 2010). In addition, some studies comparing the effectiveness of 
two different forms of care have reported only the incremental cost per QALY ratio without separately 
reporting the costs and the number of QALY gained for the forms of care being compared (Eefting et al., 
2003; Weintraub et al., 2004; Wu et al., 2007).  
Furthermore, in some studies, the follow-up measurement of HRQoL has been performed 
before recovery can be expected to be complete, e.g., as early as 1 month after the surgical procedure 
(Eefting et al., 2003). In most studies, the number of QALYs has been expressed as an average, while some 
studies have used the sum of all QALYs gained (Karlsson et al., 2009). Additionally, the time horizon used 
for calculations has varied from 6 months to the entire life expectancy. Table 4 provides an overview of these 
studies. 
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Table 4: The reporting and calculation of QALYs in published studies  
Study Dg (n) Area 
above/below 
the baseline 
HRQoL 
Whole 
AUC 
Time horizon in 
QALY 
calculation 
Reported 
number of 
QALYs 
Cost/QALY HRQoL 
measurement 
Sznajder et 
al., 2001 
At least one 
organ failure 
(121 survivors) 
 x Life expectancy 
according to the 
seriousness of 
the illness 
3.9 4 110 EQ-5D 
Eefting et 
al., 2003 
OPCAB2 (142)  x 12 months 0.790 14 188 EQ-5D 
Weintraub 
et al., 2004 
CABG (500)  x 12 months 0.694 12 831 EQ-5D 
Sharples et 
al., 2006 
Ventricular 
assist device 
(70) 
 x Life time of 
transplantation 
patients 
3.27 53 162 EQ-5D 
Wu et al., 
2007 
AVR4 (4 617) 
octogenarians 
and  
nonagenarians 
 x Estimated 
lifetime 
39 505  
______ 
Mapping 
quality of 
life scores to 
NYHA class 
I=0.85  
II= 0.71 
III =0.57 
IV = 0.43 
 
Al-Ruzzeh 
et al., 2008 
CABG1 (53) 
OPCAB2 (44) 
x   6 months 0.362 
0.379 
---------- 
----------- 
Mapping 
WHOQOL-
100 answers 
to the EQ-5D 
Graf et al., 
2008 
Cardiac arrest 
(81 survivors) 
 x Life time  1 766  13 805 Mapping SF-
36 answers 
to the Health 
Status 
Index(HSI) 
Karlsson et 
al., 2009 
Sepsis (156)  x Survival time or 
populations life 
expectancy 
5 131 2 139 EQ-5D 
Kantola et 
al., 2010 
Acute liver 
failure (90) 
x  3 years 1.44 64 732 15D 
Linko et al., 
2010 
Acute 
respiratory 
failure (288 
survivors) 
 x Survival time or 
populations life 
expectancy 
10 857 1 089 EQ-5D 
Gelsomino 
et al., 2011 
MVR3 
age ≥ 80 
age ≤ 79 
 x Estimated 
lifetime 
______  
1 391 
   516 
 
SF-36 
Yaghoubi 
et al., 2011 
Heart valve 
Homograft (30) 
Mechanical 
(30) 
 x Follow-up time 
varying 
according to the 
day of  discharge  
 
1.8 
1.13 
 
1 253 
2 629 
SF-36 
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1
 Coronary Artery Bypass Graft Surgery, 2 Off-pump coronary artery bypass, 3Mitral valve replacement, 4Aortic valve 
replacement 
 
2.4 Summary of the literature 
 
Although the improvement of HRQoL and cost-effective care are important targets for health 
care, their measurement varies. First, one of the most often used HRQoL instruments—namely, the SF-36—
is a profile instrument which does not readily allow for the calculation of the cost utility of care. Second, 
HRQoL scores measured using different generic HRQoL instruments are often regarded as universal, single-
index scores, while the scores produced using these different instruments are not similar. Although attention 
has been paid to this problem in recent years, understanding of the applicability and comparability of 
different generic instruments is still unclear in the critical care setting. Possibly due to the 2002 Brussels 
Roundtable Consensus Meeting’s recommendation, current knowledge stipulates that comparisons between 
different generic HRQoL instruments within critical care are, by and large, lacking, yet urgently needed. The 
responsiveness to change among various instruments—i.e., their ability to detect changes in HRQoL over 
time—needs to be studied in much greater detail than has been the case thus far, since a change in the 
HRQoL score is an indicator of the effect of care.  
At present, there is no gold standard for the calculation of QALYs, which has led to the use of 
variable calculation methods, differences in the estimation of baseline HRQoLs in the critical care setting 
and varying time horizons. Moreover, inadequate attention has been paid to recording the patterns of 
recovery and the development of HRQoLs during a time horizon. In addition, understanding of the 
considerable effect the use of different generic HRQoL instruments has on the number of QALYs gained or 
experienced leaves much to be desired. Given that the demand for resource-intensive critical care is 
increasing, it is crucial to understand the effect of different HRQoL instruments, calculation methods and 
assumptions on the number of QALYs and the cost per QALY gained in the critical care setting.  
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3. Aims of the study 
Treatment in the critical care setting is resource-intensive and likely to require even more 
resources in future due to increasingly demanding treatment modalities and the ageing of the population. 
Therefore, it is important to know the effectiveness and costs of different interventions. The overall aim of 
this series of studies was to identify factors causing differences and inaccuracies in the calculation of QALYs 
as a measure of effectiveness in the critical care setting. It is hoped that this will improve the quality and 
comparability of economic evaluations within the field.  
 
The specific objectives were: 
1. To compare the characteristics of two HRQoL instruments—the EQ-5D and the 15D—in the critical 
care setting. That is, are the HRQoL scores produced by the EQ-5D and the 15D interchangeable 
(study I).  
2. To assess the sensitivity of the EQ-5D and the 15D in detecting a change in HRQoL, i.e., the 
responsiveness to change after treatment in the critical care setting. That is, which of the two 
instruments—the EQ-5D or the 15D—is more suitable for the evaluation of HRQoL in the critical 
care setting in terms of discriminatory power and responsiveness to change (study I). 
3. To assess the effect of the HRQoL instrument used and the calculation method employed on the 
number of QALYs gained by treatment in the critical care setting. That is, what is the effect of the 
calculation method and the HRQoL instrument—the EQ-5D or the 15D—on the number of QALYs 
and the cost per QALY ratio (study II). 
4. To estimate the excess or reduced mortality and lifetime gained or lost in patients treated in an ICU 
or HDU or after elective surgery. That is, how can the potential excess mortality within the critical 
care setting is taken into account in QALY calculations (study IV). 
5. To evaluate the ability of routinely used predictors of operative mortality to also predict follow-up 
HRQoL and to assess the effect of patient characteristics and care-related factors on follow-up 
HRQoL. That is, can factors predicting mortality and morbidity be used to predict follow-up HRQoL 
in cardiac surgery patients (study III). 
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4. Patients and methods 
4.1 Patients 
 
The studies are based on two prospectively collected data sets of patients treated in an ICU, 
HDU or cardiac surgical intensive care unit (CSICU) at the Helsinki University Hospital. The follow-up time 
was 12 months in studies I and II, until death or 30 October 2012 in study III and 6 months in study IV. 
The data in study I consisted of all patients treated in ICU or HDU between 1 January 2003 
and 31 December 2004 (N = 3 600). They consisted of both acutely ill and electively treated critical care 
patients from all diagnostic groups of the International Classification of Diseases, 10
th
 edition (ICD-10) 
except for the group of perinatal diseases. The most common distinct diagnoses were intoxication (T36, n = 
213), peripheral atherosclerosis (I70.2, n = 196), cardiac arrest (I46.0, n = 179) and abdominal aortic 
aneurysm without rupture (I71.4, n = 106). The patient population was analysed as a whole and the data were 
gathered after an ordinary care process. 
The data in study II is a subgroup of patients from study I and includes only those patients who 
received care on an emergency basis (N = 1 990). The care was deemed to have started on an emergency 
basis if the admission to both the hospital and ICU or HDU occurred on the same day. The largest diagnostic 
group was diseases of the circulatory system (n = 701). The most common distinct diagnoses were 
intoxication (T36, n = 210) and cardiac arrest (I46.0, n = 167). All other distinct diagnostic groups included 
distinctly fewer patients. The data were analysed as an aggregate. 
The data in study III comprise two different patient populations. First, the data used in study I 
(n = 3 600) and, second, all patients treated in CSICU who returned a baseline or follow-up HRQoL 
questionnaire between 1 March and 31 December 31 2006 (n = 1 186). The total study population, thus, 
compromises of 4 786 patients. Cancer patients (n = 260), patients with an unknown diagnosis (n = 99) and 
patients from diagnostic groups that had less than 99 patients (n = 2 741) were excluded as inadequate for 
analysis. The most common diagnoses or surgical procedures were CABG (n = 498), aortic valve surgery (n 
= 253), intoxication (n = 230), cardiac arrest (n = 213), pneumonia (n = 207) and peripheral atherosclerosis 
(n = 201).  
The data in study IV consisted of 980 consecutive, elective cardiac surgery patients treated in 
CSICU between 1 March 2006 and 31 December 2007. To be included in the study, the patients had to have 
waited for the operation for at least 7 days, indicating non-urgent surgery. The most common surgical 
procedures were conventional CABG (n = 333), AVR (n = 202), CABG and valve surgery (n = 169) and off-
pump coronary artery bypass (OPCAB) (n = 118) (Table 5). 
Direct health-care costs for the patients were obtained from the Ecomed® clinical patient 
administration system (Datawell Ltd., Finland), where all costs of treatment for individual patients in the 
hospital are routinely stored. 
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Table 5. Characteristics of the patient population 
 Study I Study II Study III Study IV 
Unit ICU
1
, HDU
2
 ICU
1
, HDU
2
 ICU
1
, HDU
2
, CSICU
3
 CSICU
3
 
Number 3 600 1 990 2 741 980 
Follow-up time 12 months 12 months until death or until  
30 October 2012  
6 months 
Male (%) 62.5  62.7 68.6 70.2 
Mean age (years) 60.1  57.4 63.0 65.7 
LOS
4
 in critical 
care setting 
(median) 
2.8 2.0 2.0 1.0 
LOS
4
 in hospital 
(median) 
12.0 9.0 11.0 9.0 
Costs (median, €) 16 106 12 090 15 738 16 103 
Cost (range, €) 1 045-356 800 1 045-334 118 1 045-356 800 3 647-169 273 
1
Intensive care unit, 
2
 High dependency unit, 
3
 Cardiac surgical intensive care unit. 
4
lenght of stay 
 
Ethical approval for studies I, II and III was granted by the local Ethics Committee 
(§12/2002/4.2.2002). According to the ethics committee of the hospital, study IV did not require ethical 
approval because the study data was based on standard information gathered during the care process. 
Permission for the study was, thus, obtained from the administration of the Helsinki University Hospital 
(§69/28.05.2008). 
 
4.2 Methods 
4.2.1 HRQoL 
 
HRQoL was measured using the 15D and EQ-5D HRQoL instruments 6 and 12 months after 
treatment in studies I and II. Baseline HRQoL was, thus, not assessed by patients. The first questionnaires 
with an accompanying letter and an informed consent form were sent to patients still alive 6 months after 
treatment and they were asked to return the questionnaires in a prepaid envelope via post. Follow-up 
questionnaires were sent to those patients who had returned the 6-month questionnaire and were still alive at 
12 months. In the case of a nonresponse, one reminder was sent. 
In contrast to study I, the data from study II also included deceased patients. For patients who 
died during the 1-year follow-up time, HRQoL was assumed to have changed to 0 at the moment of death.  
Since the data did not include baseline HRQoL, it was estimated in two different ways in 
study II. Baseline HRQoL was either assumed to be 0—i.e., the patient would have died without treatment—
or it was assessed retrospectively based on information obtained from patients’ medical and nursing records 
and mapping the information onto the 15D and EQ-5D questionnaires by two health-care professionals. The 
proxy assessment was based on the status of the patient upon admission to ICU or HDU. 
Altogether, the baseline HRQoL was assessed for 112 patients in different diagnostic groups 
according to ICD-10. Infrequent diagnoses were combined into the diagnostic group of “other diseases.” The 
average for all baseline HRQoL assessments in each diagnostic group was used for analysis (Table 6). 
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Table 6. Mean proxy-assessed (by two health-care professionals) baseline HRQoL scores according to the 
15D and the EQ-5D and based on information obtained from patient records 
 
Diagnostic group EQ-5D 
mean  (range) 
15D 
mean  (range) 
Total number 
of patients 
Resuscitated patients -0.594  (-0.594 - -0.166) 0.106  (0.106 - 0.106) 17 
Neurological diseases -0.508  ( -0.594 - -0.166) 0.149  (0.106 - 0.398) 12 
Respiratory organ diseases -0.408  ( -0.594 - -0.166) 0.253  (0.106- 0.575) 13 
Intoxication -0.420 ( -0.594 - -0.430) 0.208  (0.106 - 0.459) 16 
Infectious diseases -0.465  ( -0.594 - 0.280) 0.237  (0.106 - 0.587) 14 
Gastrointestinal diseases -0.379 ( -0.594 - 0.587) 0.392  (0.106 - 0.654) 12 
Other diseases -0.248 ( -0.594 - 0.710) 0.407  (0.106 - 0.739) 12 
Vascular diseases -0.339  ( -0.594 - 0.002) 0.528  (0.240 - 0.755) 7 
Heart diseases 0.089  ( -0.594 - 0.710) 0.528   (0.106 - 0.810) 9 
Average -0.387 ( -0.594 - 0.710) 0.285  (0.106 - 0.810) 112 
 
In study IV, HRQoL was measured using the 15D once the patients were placed on the 
waiting list for surgery and 6 months post-operatively. In the case of a nonresponse, no reminders were sent 
(Table 7). 
 
Table 7. Measurement of HRQoL 
 Study I Study II Study III Study IV 
HRQoL instrument EQ-5D, 15D EQ-5D, 15D None 15D 
Baseline HRQoL Not measured Estimated None When placed on the 
waiting list 
Follow-up measurement At 6 and 12 months At 6 and 12 
months 
None At 6 months 
 
The change in HRQoL was classified according to MCID in HRQoL (studies I and IV). The 
change was coded as negative if it was ≤ -0.08 using the EQ-5D and ≤ -0.03 using the 15D and positive if it 
was ≥0.08 using the EQ-5D and ≥0.03 using 1the 5D. Other values were coded as unchanged. 
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4.2.2 QALY calculation 
 
Calculation of QALYs in study II was performed using four different calculation assumption 
sets (AS1–AS4). In Figure 3, the area under the curve—i.e., the grey area—depicts the number of QALYs 
gained using different calculation assumptions. Using calculation assumptions AS1 and AS2, the baseline 
HRQoL is assumed to be 0, while using calculation assumptions AS3 and AS4, the baseline HRQoL is the 
proxy-assessed HRQoL score reflecting the patient’s state upon admission to ICU or HDU.   
 
In AS1, HRQoL changes with treatment immediately to the level observed at the first follow-up point, t1 
(HRQoLt1), after which it changes linearly to that observed at the second follow-up point, t2 (HRQoLt2). The 
theoretical maximum number of QALYs gained during 1 year is 1: 
(AS1) QALY = HRQoLt1 * D1 + [(HRQoLt1 + HRQoLt2) / 2] * D2, 
where D1 is the duration of follow-up from baseline to the first measurement and D2 is the duration of 
follow-up from the first measurement to the second. 
 
In AS2, HRQoL changes with treatment linearly during the entire follow-up time. The theoretical maximum 
number of QALYs gained during 1 year is 0.750: 
(AS2) QALY = (HRQoLt1 / 2) *D1 + [(HRQoLt1 + HRQoLt2) / 2] *D2.  
 
In AS3, HRQoL changes with treatment immediately to the level observed at the first follow-up point, after 
which it changes linearly to that observed at the second follow-up point. The theoretical maximum number 
of QALYs gained during 1 year depends on the baseline HRQoL score: 
(AS3) QALY = HRQoLt1 * D1 + [(HRQoLt1 + HRQoLt2) / 2 * D2] – (HRQoLt0 * DFollow-up), 
where DFollow-up is the total duration of follow-up. 
 
In AS4, HRQoL changes with treatment linearly during the entire follow-up time. The theoretical maximum 
number of QALYs gained during 1 year depends on the baseline HRQoL score: 
(AS4) QALY = [(HRQoLt0 + HRQoLt1) / 2] * D1 +[(HRQoLt1 + HRQoLt2) / 2 * D2] – (HRQoLt0 * DFollow-up). 
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Figure 3. QALY calculation methods based on assumption sets 1–4. 
 
4.2.3 Statistical methods 
 
The descriptive statistics for continuous variables are reported as means, medians and ranges. 
The descriptive statistics for continuous variables with non-normal distributions are reported as medians and 
as percentages and ranges for categorical variables.  
The association between the scores for the instruments was explored using the non-parametric 
Spearman rank correlation coefﬁcient (Sarna (a), 2011), while agreement analysed using the Bland–Altman 
plot. The Bland–Altman plot is a graphical method used to compare agreement between two measurements 
by plotting the difference on the horizontal axis and the average of the measurements on the vertical axis. 
The reference lines show, respectively, the mean difference between the measurement and ±1.96 standard 
deviations from the mean difference (Bland and Altman, 1986).  
Paired samples t-test was used to test the statistical significance of the differences in the mean 
number of QALYs obtained using the 15D and the EQ-5D. The Wilcoxon signed-rank test was used to test 
the statistical significance of the difference in the medians and distributions of the 15D and EQ-5D scores.  
The discriminatory power of the instruments was explored by comparing the proportion of 
patients obtaining the ceiling score of 1 (ceiling effect) and the number of different health states. The 
agreement in the change in HRQoL scores (study I) and the direction of the change for the HRQoL scores 
between the baseline and 6-month measurements as observed in the data and predicted by the models (study 
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IV) were tested using the McNemar–Bowker test and the Cohen’s kappa. The McNemar–Bowker test is a 
related samples test used when the measurement level is nominal and the variable includes more than two 
classes. It is used to test whether the matrixes of the measurements are symmetric. The Cohen’s kappa is 
used with nominal variables to test the difference between observed agreement and random agreement. The 
Cohen’s kappa varies from -1 to 1. A value of 1 means full agreement was found, 0 represents random 
agreement and a value of -1 indicates that the agreement is less than random indicating disagreement. A 
good agreement between measures requires a kappa value of at least 0.6 (Sarna (a), 2011). 
A chi-squared test was used to determine whether the distribution of proxy-assessed patients 
across diagnostic groups deviated from that of all ICU patients across these groups. The Chi² test is an 
independent samples test to measure the differences between groups when the measurement level is nominal. 
The estimation is based on differences between observed and expected frequencies. The expected 
frequencies are calculated using probability mathematics (Ranta et al., 2005; Sarna (a), 2011).  
The probability of death (study IV) was predicted using binary logistic regression using the 
maximum likelihood method. The binary logistic regression was used since the output variable was 
qualitative and had two possibilities: death occurs (1) or does not occur (0). The result of the analysis is the 
probability that the event—in our case, death—occurs in relation to not occurring. The maximum likelihood 
method generates coefficients which most likely produce the observations of the sample. The exponentiated 
coefficients are odds ratios, which express a percentage change in the probability of the event when the value 
of the explanatory variable changes 1 unit (Sarna (b), 2011). 
The probability of death was explained in four stages. First, the patient characteristics before 
cardiac surgery, including a dummy value for coronary artery bypass grafting (CABG = 1, other heart 
surgery = 0), were entered in to the model. Second, a more parsimonious model including only those 
variables whose coefficients were statistically significant in the first stage was run. Third, in addition to the 
variables with statistically significant coefficients in stage one, the ICU-related variables were entered. 
Fourth, a more parsimonious model including only those variables whose coefficients were statistically 
significant in stages one and three was run. 
The likelihood ratio test (LR-test) was used to determine whether model 2 produces a 
significantly better fit to the data than model 1 alone. The LR-test statistic is defined as (-2*Log-likelihood 
of model 1 + 2*Log-likelihood of model 2). The probability distribution of the test statistic is approximately 
a chi-squared distribution with df2 – df1 degrees of freedom, where df1 and df2 represent the number of free 
parameters from models 1 and 2, respectively. The LR-test is more appealing than the F-test when large 
samples are involved since it does not require an assumption of normality (Pindyck and Rubinfeld, 1991). 
For the same purpose, the correctness of classifications compared with the observed data was also analysed. 
The variance in HRQoL (the 15D score) at the 6-month follow-up among those who were alive at that time 
was explained using Tobit regression models by applying a similar four-stage approach with an LR-test to 
determine whether model 2 produces a significantly better fit to the data than model 1 alone. The Tobit 
regression was used because the follow-up 15D score is continuous but restricted, i.e., the maximum value is 
1. The Tobit regression generates coefficients using the maximum likelihood method (Greene WH, 1998).  
The relative survival method was used to estimate the possible excess mortality in different 
diagnostic groups in comparison to the population’s mortality. The relative survival ratio (RSR) is calculated 
by dividing the observed interval-specific survival proportions of the patients by the expected ones in a 
comparable reference population. The expected survival proportions were derived from the mortality rates of 
the general population of Finland and stratified by sex, age and calendar time. We used RSR to resolve 
problems related to censoring caused by the limited follow-up times. The annual, bias-reduced relative 
survival method registers survival separately for each calendar year and survival time is estimated by using 
narrow age groups instead of the entire patient population. The annual, bias-reduced RSR method reveals the 
variation and disappearance of possible excess mortality during the follow-up time more easily than 
cumulatively reported survival. The narrow age groups dismiss the bias connected with informative 
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censoring, i.e., young patients’ longer follow-up times and older patients’ greater risk of death (Seppä and 
Hakulinen, 2009).  For the prediction of the mean survival times, the cumulative observed survival 
proportions of the patients were estimated according to the follow-up time. Thereafter, the survival of the 
patients was extrapolated based on three different assumptions: 1) patients had the same mortality rates as 
comparable persons in the general population with respect to sex, age and calendar time, 2) patients had a 
1% excess mortality and 3) patients had a 2% excess mortality during the rest of their lives.  
A summary of the statistical methods used in the studies is given in Table 8. 
Table 8. Statistical methods used by study and purpose 
Study Purpose Method 
I To estimate the association between the 
HRQoL scores for the 15D and the EQ-5D 
  Spearman rank correlation 
I To estimate the agreement between the 
HRQoL scores of the 15D and EQ-5D 
  Bland-Altman plot 
I & II To test the statistical significance of the 
difference in the medians and distributions 
of the 15D and EQ-5D scores.  
 
  Wilcoxon signed-rank test 
I & IV To test whether the 15D and the EQ-5D 
yield a statistically significant similar 
result for the changes in HRQoL 
 
  McNemar-Bowker test 
I & IV To test the level of agreement in the 
direction of change of the 15D and the 
EQ-5D scores 
  Cohen’s kappa 
II To test the statistical significance of  the 
differences in the mean number of QALYs 
obtained using the 15D and the EQ-5D 
 
  Paired samples t-test 
II To test whether the distribution of proxy-
assessed patients across diagnostic groups 
deviates statistically significantly from 
that for all ICU patients across  groups 
 
   Chi² test 
IV To predict the probability of death by a 
certain point in time 
  Binary logistic regression 
IV To compare the fit to the data for two 
nested models 
  Likelihood ratio test 
IV To explain the variance in the follow-up 
HRQoL scores 
  Tobit regression 
III To estimate excess mortality   Relative survival  ratio 
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The data were analysed using IBM SPSS Statistics (versions 17, 18 and 20), Limdep (version 7.0) and R-
software. P-values of 0.05 were considered statistically significant. 
 
4.2.4 Assessment of other parameters 
 
Other parameters used in study III 
Mortality was reported per 100 life years because the follow-up time varied between patients as the entry 
into the study occurred during several years. Mortality per 100 years was calculated by dividing the summed 
survival time by the observed mortality and multiplying the remainder by 100 years. The mortality rate was 
calculated separately for each diagnostic group and gender. 
Clinical parameters used in study IV 
The New York Heart Association classification (NYHA). NYHA is a classification system used to assess 
the stage of heart failure, ranging from class I to IV and is based on symptoms related to physical activity. 
Class I refers to no symptoms and no limitation, class II slight limitation and class III marked limitation in 
ordinary physical activity. Class IV means severe limitations even at rest (see 
http://www.abouthf.org/questions_stages.htm for further details). 
The European method for cardiac operative risk evaluation (EuroSCORE). Cardiac surgery patients’ 
mortality risk was measured using EuroSCORE. EuroSCORE I was used, which was in use in the years 2006 
and 2007. It consists of patient-related factors, the preoperative clinical state and cardiac-related factors. 
Patient-related factors include age, gender and co-morbidities such as diabetes mellitus, lung disease and 
impaired renal function. Cardiac-related factors include conditions such as recent myocardial infarction and 
left ventricular function. Surgery-related factors include the surgical procedure completed and the urgency of 
the procedure. The lowest possible score is 0, while a score of 6 or higher indicates a high risk level (see 
http://www.euroscore.org/calc.html for further details). 
Sequential Organ Failure score (SOFA). The SOFA is used to assess the mortality risk in critically ill 
patients, and is based on the functioning of the respiratory, cardiovascular, hepatic, coagulation, renal and 
neurological systems. In it, each dimension is graded from 0 (normal) to 4 (most abnormal), where the total 
score can fall within the range of 0 to 24. The highest value of the SOFA was used in the analysis because it 
has been shown to correlate with 30-day mortality in cardiac surgery patients (Pätilä et al., 2006).   
Body mass index (BMI). BMI was used to assess patients’ nutritional status. It is calculated by dividing an 
individual's body mass (in kilograms) by the square of his/her height (in metres). Values under 18.50 indicate 
that an individual is underweight, while values above 25.00 indicate an individual is overweight (see 
http://apps.who.int/bmi/index.jsp?introPage=intro_3.html for further details). In critically ill patients, being 
underweight is associated with increased mortality (Garrouste-Orgeas et al., 2004). 
The Therapeutic Intervention Scoring System (TISS-28). TISS-28 was used to measure the nursing 
workload during a patient’s CSICU stay. The instrument consists of six categories: basic activities, ventilator 
support, cardiovascular support, renal support, neurological support, metabolic support and specific 
interventions. These categories are divided into 28 activities performed by nurses in ICU. Activities 
performed by nurses include, for example, dressing changes, care of drains and taking care of multiple 
vasoactive medications (Reis et al., 1996). 
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The Richmond Agitation and Sedation Scale (RASS). RASS was used to assess restlessness and deep 
sedation during a patient’s CSICU stay. It is a 10-point scale describing a patient’s state, ranging from alert 
and calm to combative or unarousable. The RASS scale ranges from -5 to 4, where negative values indicate 
sedation, 0 signifies that the patient is alert and calm and 1 and higher represent different levels of 
restlessness (Ely et al., 2003). Patients with RASS values of 1 or higher were classified as having 
experienced restlessness. Patients with a RASS value of -4 or -5 and an ICU stay longer than 2 days were 
classified as deeply sedated. RASS values of -4 and -5 during the first 2 days were ignored because, after a 
surgical procedure, patients are normally deeply sedated.  
The Verbal Rating Scale (VRS). VRS was used to assess pain. The VRS scale ranges from 0 to 4, where 0 
refers to no pain, 1 represents slight pain, 2 refers to moderate pain, 3 signifies severe pain and 4 indicates 
unbearable pain. VRS is also suitable for older individuals (Pesonen et al., 2008). For the analysis, patients 
were classified as having experienced severe or unbearable pain if their VRS scores were 3 or 4.  
Nursing records. Structured, electronic nursing records were used to gather additional information about 
restlessness and the experience of pain. Patients were classified as restless if nursing reports included the 
words “disorientated”, “confused” or “agitated” and as having experienced pain if the nursing reports 
indicated that the patient was in pain. 
Other parameters. In addition, information was collected on complications (renal, neurological, respiratory, 
arrhythmia, urgent sternotomy and re-operation) that occurred during a patient’s ICU stay and on the use of 
the intra-aortic balloon pump (IABP), the duration of ventilator treatment and the occurrence of nosocomial 
infections. The definition of a renal complication was based on the need for RRT or high doses of 
furosemide, and that of arrhythmias as arrhythmias other than atrial fibrillation and requiring medical or 
pacemaker interventions (Suojaranta-Ylinen et al., 2006). Delirium coinciding with a physical incident such 
as a brain infarction was classified as a neurological complication. 
The clinical information in study IV was obtained from the Care Suite® clinical patient information system 
and the administrative database of the hospital. Information concerning patient care was gathered during the 
ordinary care process in all studies. 
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5. Results 
5.1 Patients 
The data from study I consisted of 929 patients who responded to both HRQoL questionnaires 
at the 6- and 12-month follow-up points. This represents 36% of the 2 600 patients alive at the time of the 
survey. Most of the patients were male (63%) and the mean (median) age was 60 (62) years old with a range 
of 16 to 92 years old. The median (mean) length of stay in the critical care setting was 2 (4.9) days ranging 
from less than 1 day to over 2 months. The median (mean) length of stay in hospital was 13 (18.7) days with 
a range of 1 day to 6 months. The median (mean) total cost for all treatment related to the illness episode was 
17 871 (24 252) € ranging from about 2 000 € to almost 230 000 €.  
Respondents and non-respondents differed statistically significantly regarding the mean age (p 
< 0.001), length of hospital stay (p < 0.001) and the cost of treatment (p < 0.001). Respondents were on 
average 4 years older (60 vs. 56), their median length of hospital stay was 1 day longer (13 vs. 12) and the 
median total costs for respondents was 2 138 € higher (17 871 € vs. 15 789 €).  
The data from study II included patients whose treatment started on an emergency basis in 
ICU or HDU and who returned the completely filled HRQoL questionnaires both at  6 and 12 months or 
patients who had died before the first follow-up point (i.e., at 6 months). For patients who had died before 
the first follow-up point (n = 451), the HRQoL score was set to 0. In total, both follow-up HRQoL 
questionnaires were returned by 486 patients.  Thus, the final data set comprises 937 patients, 47.1% of the 
original 1 990 eligible patients. Most of the patients were male (62%) and the mean (median) age was 61 
(58) years old with a range of 16 to 98 years old. The median (mean) length of stay in the critical care setting 
was 3 (5.5) days ranging from less than 1 day to over 2 months. The median (mean) length of hospital stay 
was 9 (14.0) days ranging from 1 day to over 9 months. The median (mean) cost of the hospital stay was 
14 392 (21 123) € ranging from about 1 000 € to over 330 000.  
Respondents and non-respondents differed statistically significantly regarding the mean age (p 
< 0.001), length of hospital stay (p < 0.001) and total cost of treatment (p < 0.001). Respondents were on 
average 7 years older (61 vs. 54), for respondents the median length of stay in the critical care setting was 1.0 
day longer (3.0 vs. 2.0), and the median total costs 1 954 € higher (14 392 € vs. 12 438 €).  
The data from study III included patients treated in the critical care setting and who survived 
for more than 30 days (N = 2 445). Most of these patients were male (68.6%). For none of the diagnostic 
groups was the proportion of women clearly larger than that of men. The mean age for males was 62.4 years 
with a range of 16.4 to 89.4 years, while females had a mean age of 64.0 years ranging from 15.4 to 97.5 
years. The median (mean) length of stay in the critical care setting was 2 (4.0) days ranging from less than 1 
day to over 2 months. The median (mean) length of hospital stay was 10 (15.5) days ranging from 1 day to 
almost 6 months. The median (mean) cost of the hospital stay was 15 738 (22 559) € with a range of about 1 
000 € to over 356 800 €.  On average, the follow-up time was 5.9 years varying from 1 month to almost 10 
years. The estimation of excess mortality is based on 14 381 person-years, which was 9 836 person-years for 
males and 4 545 for females. 
The data from study IV consisted of cardiac surgery patients treated in CSICU, who waited for 
the scheduled surgery for 7 or more days and who answered both the baseline and 6-month follow-up 
HRQoL questionnaires or those who died during the follow-up time. The follow-up questionnaire was 
returned by 544 patients and 27 patients died during the follow-up. Thus, the final data set comprises 571 
patients 58.3 % of the 980 eligible patients.  
Most of the patients were male (70%) and the mean age was 66 years ranging from 21 to 90 
years old. The median (mean) length of stay in CSICU was 1 day (2.8 days) ranging from less than 1 day to 
over 2 months. The median (mean) length of stay in hospital was 9 (11.5) days with a range of 2 days to 
more than 2 months. The median (mean) cost of the hospital stay was 15997 (20 978) € ranging from about  
5 574 € to over 169 273 €.    
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The preoperative status of respondents and non-respondents differed statistically significantly 
only regarding the NYHA class (p = 0.002). Non-respondents more often fell into NYHA class IV than 
respondents (18.4% vs. 9.5%). With regards to the CSICU-related variables, respondents experienced severe 
or unbearable pain more often than non-respondents (p = 0.049). Among respondents, 22.6% experienced 
severe or unbearable pain compared to 17.2% of non-respondents (Table 9). 
Table 9. Comparison of respondents and non-respondents in the studies 
 Study I Study II Study III Study IV 
Patients (n) 929 937 2 445 571 
Response rate (%) 36.0 47.1 Register-based 
study 
58.3 
Male (%) 63.0 62.0 68.6 70.1 
Age (mean) 60.0 61.1 62.9 66.2 
LOS
1 
in critical care setting 
(median) 
2 3 2 1 
LOS
1 
in hospital (median) 13 9 10 9 
Costs (median) 17 871 13 251 15 738 15 998 
Statistically significant 
difference compared to the non-
respondents 
Age*** 
LOS
1 
in hospital*** 
Costs* 
Age*** 
LOS
1 
in 
critical care 
setting*** 
Costs* 
 
 
 
-------- 
NYHA class** 
Severe or unbearable 
pain* 
1
Lenght of stay, p < 0.05* p < 0.01 **,   p <0.001*** 
 
5.2 Agreement on HRQoL scores between the EQ-5D and the 15D 
 
The instruments gave a different picture of patients’ HRQoL. The HRQoL scores were 
uniform only in a minority of cases and neither of the instruments produced systematically higher or lower 
scores than the other. Although the ranking of the HRQoL scores (p < 0.001) was quite similar, the mean 
HRQoL scores (p < 0.001) and the distributions of the HRQoL scores (p < 0.001) differed in a statistically 
significant manner between instruments (study I).  
The mean HRQoL was higher when assessed using the 15D compared to the EQ-5D. The 
mean HRQoL score was 0.832 at 6 months and 0.835 at 12 months when measured using the 15D and 0.731 
and 0.735, respectively, when measured using the EQ-5D. The distribution of the HRQoL scores produced 
using the EQ-5D was discontinuous, had a long tail with low HRQoL scores and a peak with the highest 
possible HRQoL score. The long tail is partly explained by health states WTD, i.e., negative HRQoL scores. 
The number of negative HRQoL scores was about 3% using the EQ-5D. The distribution for the 15D was 
continuous, slightly skewed to the right and very low HRQoL scores were missing. The Bland–Altman 
graphical method verified the differences between the instruments.  
The dissimilarities between the scores for the instruments were particularly evident at both 
ends of the measurement scales (Figure 4). 
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Figure 4. Agreement between the 15D and the EQ-5D scores at 6 months illustrated using a Bland–Altman 
plot (the horizontal lines represent the mean difference between the scores for the instruments ± 1.96 SD of 
the mean). 
 
5.3 Comparison of the discriminatory power and responsiveness between the EQ-5D and the 15D 
 
The discriminatory power was better with the 15D than with the EQ-5D. The ceiling effect—
i.e., an HRQoL score equal to 1—occurred more infrequently using the 15D than with the EQ-5D. Using the 
15D, 5.8% of patients at 6 months and 7.8% of patients at 12 months after treatment scored at the ceiling. 
The corresponding figures for the EQ-5D were 26.2% and 28.6%, respectively. Furthermore, the 15D was 
more sensitive in distinguishing between different health states than the EQ-5D. Using the 15D, the number 
of different health states was 767 at 6 months and 745 at 12 months. The corresponding figures for the EQ-
5D were 79 and 70 (study I), respectively.  
Although on average there was no change in the mean HRQoL score between 6 and 12 
months, changes were observed at the individual level. The magnitude of change in the HRQoL scores was 
almost three-fold using the EQ-5D compared to the 15D. Using the EQ-5D, the magnitude of change varied 
from -0.82 to 0.88, while with the 15D, the range was -0.33 to 0.32. A clinically important change (equal or 
more than MCID) in the HRQoL scores was detected more often using the 15D than the EQ-5D. Using the 
15D, 46% of patients were in the group of unchanged HRQoL, whereas the corresponding figure for the EQ-
5D was 61%. Thus, the 15D was more sensitive to detecting a clinically important change, but the quantity 
of change was clearly smaller compared to that seen when using the EQ-5D. 
The instruments yielded a different picture for the clinically important change in the HRQoL 
score (p < 0.001). HRQoL measured using the 15D improved for 29.3% of patients. Among those patients, 
the EQ-5D classified 1.6% into the group of deteriorated HRQoL and 16.8% into the group of unchanged 
HRQoL. The classification was consistent between instruments in 10.9% of all cases in the group of 
improved HRQoL according to the 15D. As stated above, the EQ-5D classified 61.0% of the patients into the 
group of unchanged HRQoL. Among those patients, the 15D classified 11.8% as belonging to the group of 
deteriorated HRQoL and 16.8% as falling into the group of improved HRQoL. There was agreement 
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between the instruments regarding the direction of change in 53.4% of cases; consequently, the Cohen’s 
kappa was low 0.247 (p < 0.001) indicating a fair degree of agreement between the instruments (study I).  
 
5.4 The effect of the HRQoL instrument on the number of QALYs 
 
 The 15D and EQ-5D instruments performed differently when using various calculation 
assumptions. The most significant differences between the instruments were detected when applying 
calculation assumptions AS3 and AS4, which both used proxy-assessed baseline HRQoL scores. Applying 
AS3 and AS4, the 15D generated the smallest and the EQ-5D generated the largest number of QALYs. 
Using AS1 and AS2, in which the baseline HRQoL was assumed to equal 0, the number of QALYs was 
quite comparable to the distinction that a QALY loss occurred only when using the EQ-5D. In that case, the 
QALY loss indicates the existence of health states WTD. Consequently, a QALY loss using the 15D 
occurred only when the proxy-assessed baseline HRQoL scores were used (AS3 and AS4). 
In addition, the maximum number of QALYs gained revealed dissimilarities between the 
instruments. The maximum number of QALYs gained during a year was 1 QALY when using the 15D and 
1.6 QALYs when using the EQ-5D. The EQ-5D produced more than 1 QALY a year when calculation 
assumptions AS3 and AS4 (using the proxy-assessed baseline HRQoL score) were employed. The 
percentage of cases in which more than 1 QALY per year was found reached 30.5% under AS3 and 7.4% 
under AS4. Furthermore, when using calculation assumptions AS1 and AS2 (the baseline HRQoL was 0), 
the way of recovery had an effect on the maximum number of QALYs gained. Applying AS1, the maximum 
QALY gain was 1 and 0.750 when applying AS2 irrespective of the instrument used (study II). 
 
5.5 The effect of the calculation method on the number of QALYs and the cost per QALY ratio 
 
The calculation method used (AS1–AS2) had a clear effect on the number of QALYs (p < 
0.001) irrespective of the instrument used (the 15D or the EQ-5D). The mean number of QALYs in 1 year 
varied from 0.178 (AS4) to 0.419 (AS1) using the 15D and from 0.275 (AS2) to 0.550 (AS3) using the EQ-
5D. As a consequence, the cost per QALY ratio varied according to the calculation assumption employed, 
i.e., according to the baseline HRQoL and the way in which recovery was assumed to have taken place. The 
cost per QALY ratio for the 15D was the lowest (50 412 €) when applying AS1 (the baseline HRQoL was 0 
and the recovery took place immediately) and for the EQ-5D (38 405 €) when applying AS3 (the baseline 
HRQoL was proxy-assessed and the recovery took place immediately). The highest cost per QALY ratio for 
the 15D (118 688 €) was found when applying AS4 and for the EQ-5D (76 811 €) when applying AS2 (study 
II) (Table 10). 
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Table 10.  The cost per QALY ratios for the 15D and the EQ-5D applying different calculation assumptions 
(cost in €) 
  
          Cost/QALY ratio  
         15D              EQ-5D 
Difference between the 
instruments  
           (€)                       (%) 
AS1 50 412 57 713 -7 301 14.5 
AS2 67 271 76 811 -9 540 14.2 
AS3 90 657 38 405 52 252 57.6 
AS4 118 668 51 269 67 399 56.8 
 
 
5.6 The effect of excess mortality and follow-up time on the extrapolated life expectancy 
 
The relative survival method disclosed the excess mortality in critical care patients compared 
with most of the cardiac surgical patients. The excess mortality differed between diagnostic groups and 
varied over time without a predictable trend. The most pronounced excess mortality was seen in gastric ulcer 
patients, which varied from 5% to 16%, and in pneumonia patients, which varied from 2% to 13%. Another 
extreme was off-pump patients, who in comparison to the population were at least to some degree spared 
from death. 
In extrapolating lifetime, the duration of the follow-up time had an effect on life expectancy. 
In diagnostic groups with excess mortality, the use of short follow-up times—e.g., 3–5 years instead of 9 
years—gave a longer life expectancy than longer follow-up times (study IV).  
 
5.7 The ability of the indicators predicting mortality to predict follow-up HRQoL 
 
Of the variables describing the preoperative state including the dummy variable for CABG 
versus other heart surgeries performed, EuroSCORE predicted the probability of death during the 6-month 
follow-up (model 1) in a statistically significant manner. Of the ICU-related variables, renal, respiratory and 
neurological complications as well as urgent sternotomy turned out to be additional significant explanatory 
factors (model 2). The LR-test indicated that the fit of model 2 to the data was significantly better than that 
of model 1 alone (chi-square = 67.259, df = 5, p < 0.001). Model 1 was not able to correctly predict a patient 
as being dead (0% correct, total percentage correct 95.9%), whereas model 2 correctly predicted 99.3% of 
patients as being alive, and correctly predicted 30.4% as being dead (total percentage correct, 96.4%).  
Of the variables describing the pre-operative state including the dummy variable for CABG 
vs. other heart surgeries performed, being male, having diabetes mellitus and the baseline 15D score  
explained the post-operative variance of HRQoL at the 6-month follow-up (model 1)  in a statistically 
significant manner. ICU-related variables, severe or unbearable pain and restlessness during treatment in ICU 
were found to be additional statistically significant explanatory factors (model 2). The LR-test indicated that 
the fit of model 2 to the data was significantly better than that of model 1 alone (chi-square = 25.622, df = 5, 
p < 0.001).  
Regarding the clinically important change in the HRQoL scores between the baseline and 6-
month follow-up measurements, the observed data and the predictions from model 1 had the same direction 
in 63.4% of patients. Overall, the observed data and the predictions using model 1 resulted in a different 
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picture for the changes (McNemar–Bowker = 29.629, p < 0.001) and the agreement between them was poor 
(kappa = 0.264, p < 0.001). The observed data and the predictions from model 2 had the same direction in 
63.3% of patients. The observed data and the predictions from model 2 resulted in a different picture for the 
changes (McNemar–Bowker = 22.612, p < 0.001) and the agreement between them was poor (kappa = 
0.266, p < 0.001). The predictions using models 1 and 2 resulted in a similar picture for the changes 
(McNemar–Bowker = 1.377, p = 0.711) and the agreement between them was quite good (kappa = 0.690, p 
< 0.001). Thus, model 2 was not better than model 1 in predicting the clinically important changes in 
HRQoL. 
Among the scheduled cardiac surgery patients alive at the 6-month follow-up point, 22.6% 
had experienced severe or unbearable pain and 14.4% experienced restlessness. For patients who had 
experienced severe or unbearable pain, the mean follow-up HRQoL score was 0.844 (SD ± 0.10) and 0.823 
(SD ± 0.123) for patients who had experienced restlessness. For patients, who were free from both 
symptoms, the mean follow-up HRQoL score was 0.886 (SD ± 0.098) (study III).  
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6. Discussion 
6.1 Main results 
Our findings corroborate the assertion that the number of QALYs is not a universal 
measurement, but depends on how the factors taken into account in QALY calculation are chosen and 
defined. Thus, an acceptable threshold for the cost per QALY ratio is difficult to establish as long as QALY 
calculation methods are not standardised. Additionally, the costing methodology needs to be standardised. 
The 15D showed more discriminatory power and responsiveness to change than the EQ-5D in the critical 
care setting. Furthermore, the 15D performed more consistently using different calculation methods than did 
the EQ-5D. The inconsistency of the EQ-5D in QALY calculations is caused by the negative HRQoL scores 
it can produce. To allow for comparisons between the results from different studies, agreement is needed on 
how the baseline HRQoL score in studies from critical care setting is defined.  
 
6.2 The discriminatory power and responsiveness to change of the EQ-5D and the 15D 
 
The better discriminatory power and responsiveness to change of the 15D is most likely 
explained by the richer health state descriptive system in comparison to that of the EQ-5D. For example, 
ventilator treatment is a dominant form of care in the critical care setting, yet the EQ-5D does not include a 
dimension concerning breathing. Since patients treated in the critical care setting represent a wide spectrum 
of medical specialties, one would assume that a more comprehensive HRQoL instrument than the EQ-5D 
would be more appropriate for describing the health states of the patients cross-sectionally as well as changes 
in them over time (study I). The discriminatory power of the 15D is superior to that of the EQ-5D in this 
patient group. This has also been shown to be true in many other patient groups. The lower discriminatory 
power of the EQ-5D is at least partly explained by the pronounced ceiling effect (Stavem et al., 2001; 
Stavem et al., 2005; Kattainen et al., 2005; Saarni et al., 2006; Moock and Kohlmann, 2008; Färkkilä et al., 
2013; Torvinen et al., 2013). This was also the case even in the patient group studied in which one would not 
a priori expect such a high percentage with a score of 1 (“full health”) as the group which was treated in ICU 
or HDU for serious, even life-threatening conditions just 6 months earlier.  
The distribution of HRQoL scores differed between the instruments suggesting that reporting 
the mean value alone may not provide an adequate picture of the patients’ HRQoL. Consequently, in 
addition to the mean values, the distribution of HRQoL scores should be reported. It is also evident that the 
distribution of the EQ-5D scores is usually such (e.g., discontinuous, two- or three-peaked or with a high 
ceiling effect) that conventional statistical methods are not suitable for data analysis.  
The EQ-5D was not sensitive in detecting clinically important changes and most of the 
patients were in the group of unchanged HRQoL. The range of changes varied from -0.82 to 0.88 with an 
average of 0.005. However, when a clinically important change occurred, the change in the overall score was 
large. This is a direct result of the health state descriptive system and the UK TTO valuation algorithm: due 
to the inclusion of only three levels per dimension, the distances between the levels are value-wise quite 
great. If the instrument is able to detect a change from one level to another, the change in the overall score is 
automatically quite large. This phenomenon is accentuated if a change takes place to or from level 3 on any 
dimension — then, the score changes by an additional 0.269 points in either direction, respectively, due to 
the N3 term (Dolan, 1997).  
The 15D was sensitive in detecting clinically important changes, but the mean change in the 
HRQoL score remained modest. The range of changes varied from -0.33 to 0.32 with an average of 0.003. 
Thus, for both the 15D and the EQ-5D, the mean change was almost 0 and reveals nothing about the 
important difference in the distribution of patients between those whose HRQoL improved, remained 
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unchanged or deteriorated. In this respect, the instruments yield a clearly different picture and the agreement 
between them is only fair. Reporting the distributions for changes in scores is quite informative; 
unfortunately, thus far, this has not been a common way of reporting results. It would, however, promote the 
allocation of health-care resources to patients who can benefit from treatment. Such information could also 
help to develop care processes. 
 
6.3 Calculating QALYs 
 
According to our results, in addition to the instrument used, the calculation assumptions 
concerning the baseline HRQoL, the path to recovery and whether QALYs experienced (the entire area 
under the curve) or gained (the difference between the baseline and follow-up HRQoL) were assessed greatly 
influenced the number of QALYs. It is unfortunate that studies reporting the effectiveness of care do not 
normally clearly state the calculation methods used in quantifying QALYs (Richardson and Manca, 2004; 
Schwappach and Boluarte, 2007; Rodriguez et al., 2011) despite the fact that comparisons of the results from 
different studies and making conclusions based on them require transparent reporting. 
The difference between various calculation methods—i.e., whether QALYs experienced or 
gained are explored—is clear when using HRQoL instruments operating with positive values such as the 
15D. The number of QALYs experienced is higher compared to the number of QALYs gained. In our studies 
the average number of QALYs was almost twofold when QALYs experienced were assessed compared to 
QALYs gained. The issue, however, is different when HRQoL instruments producing negative scores are 
used. In the material used here, the EQ-5D produced fewer QALYs when QALYs experienced were assessed 
compared to those gained.  
When reporting QALYs experienced, one must bear in mind that the effect of care is rarely 
directed to all dimensions of HRQoL and that the follow-up HRQoL is affected by factors prevailing before 
treatment, i.e., the baseline HRQoL. Assessing QALYs gained more accurately combines the observed 
change in the HRQoL score to the care delivered and also reflects society’s possible preference for allocating 
resources to the treatment of worse-off patients (Nord et al., 2009). Given that the baseline HRQoL has such 
a significant effect on the follow-up HRQoL, consensus on how to define the baseline HRQoL is highly 
desirable. It is likely that those acutely ill patients for whom the need for intensive care is the consequence of 
imminent organ failure can assess their HRQoL independently for themselves. The question on how to 
define baseline HRQoL is, thus, relevant only in patients already experiencing organ failure.  
In addition to the problem of how to quantify the baseline HRQoL, the calculation of QALYs 
experienced or gained is affected by assumptions concerning recovery. If the recovery process is assumed to 
take place immediately and the baseline HRQoL is assumed to be 0, the calculation of QALYs experienced 
makes it possible to experience 1 QALY within a year, whereas if the recovery is assumed to take place 
linearly, the maximum number of QALYs experienced can only be 0.750. Achieving the latter assumes that 
the measurement of HRQoL takes place at 6 and 12 months after the baseline measurement. 
The reasoning regarding how recovery takes place is often lacking in studies reporting on the 
effectiveness of care. The assumption most often used within critical care—i.e., that recovery materialises at 
the start of care—is presumably too optimistic. It is evident that the way in which and the time during which 
recovery takes place vary between different diseases and, thus, the calculation method used should reflect 
reality. It is evident that the follow-up time points for assessing HRQoL should be tailored, if possible, to 
mimic the expected pattern of recovery for individual diseases. Nevertheless, the approach used for defining 
the pace of recovery should be reported clearly and openly.  
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6.4 Baseline HRQoL in the critical care setting 
 
According to previous literature and our results, the baseline HRQoL predicts the follow-up 
HRQoL. Consequently, assumptions about the baseline HRQoL have significance for the calculation of the 
quantity of QALYs. Within critical care, the approach used for the determination of baseline HRQoL is, 
thus, of vital importance.  
Because of the difficulties in obtaining baseline HRQoL in the critical care setting, the 
baseline HRQoL has sometimes been ignored and only the follow-up HRQoL has been used in the 
evaluation. In such cases, it has usually been compared to the population’s HRQoL (Kvale et al., 2003; 
Stricker et al., 2005; Deja et al., 2006; Ringdal et al., 2009; Linko et al., 2010; Orwelius et al., 2010; 
Timmers et. al 2011). The population, however, is probably not an optimal source for comparison since 
HRQoL for healthy people may be better than that for individuals after a serious illness. As a consequence, 
the use of the population’s HRQoL as a comparison might provide an estimate which is too pessimistic 
regarding the effectiveness of critical care.  
Another assumption—namely, that without treatment the patient would die and, consequently, 
the baseline HRQoL is 0 (Graf et al., 2005; Linko et al., 2010; Peek GJ et al., 2009)—is also inaccurate. 
First, the result is the same irrespective of whether QALYs experienced or gained are calculated. Second, the 
entire scale of the instrument extending to the negative side is not in use. If health states WTD are considered 
possible, one would expect that these occur primarily at the beginning of intensive care when the acutely ill 
patient is often not able to breathe spontaneously, is unable to express her-/himself and is totally dependent 
on her/his caregivers. Third, critical care is directed to patients with the potential to recover, not to those 
dead. Thus, the initial value of 0—i.e., equivalent to being dead—is inappropriate. Furthermore, patients 
requiring intensive care for different reasons must be in a comparable position regarding the assessment of 
the effectiveness of care.  
Additionally, the assessment of baseline HRQoL by professionals at the start of care is 
problematic, especially in relation to the assessment of mental dimensions such as depression and 
dimensions concerning patient experiences such as pain. However, some dimensions, such as moving, 
breathing and usual activities, can certainly be assessed by proxy quite accurately. Despite its drawbacks, the 
assessment of baseline HRQoL by proxy may better reflect reality than other alternatives. Consensus 
regarding the assessment of mental dimensions and dimensions concerning patients’ experiences, however, 
is needed in order to enable robust comparisons between different HRQoL and cost-utility studies.  
HRQoL prevailing months before critical care assessed by proxy has not been used in QALY 
calculations, although it has been measured in some studies. One reason for this might be that it has been 
higher than the follow-up HRQoL, suggesting that there is no benefit from receiving critical care. It is likely 
that the HRQoL prevailing months before critical care does not necessarily reflect the health state prevailing 
when critical care starts. This applies to all groups of critical care patients, i.e., acutely ill patients with and 
without failed vital functions as well as scheduled surgical patients. The assessment of the baseline HRQoL 
in the critical care setting may require different presumptions depending on the specific patient population.  
 
6.5 Problems concerning negative HRQoL scores 
 
In relation to the theory of QALY according to which 1 QALY represents a year in perfect 
health, negative HRQoL scores cause problems. Due to negative HRQoL scores, the number of QALYs 
gained or lost within a year can be larger than 1 QALY, thus dismissing the rationale for QALYs. When 
using the EQ-5D with the UK TTO valuation algorithm, the maximum number of QALYs gained is 1.6 
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during a year since the scale of the EQ-5D extends from -0.594 to 1. In addition, a change from a negative 
HRQoL score to death implies an improved HRQoL and, consequently, a QALY gain. Furthermore, a 
decreasing negative HRQoL score between the baseline and follow-up—e.g., from -0.3 to -0.1—indicates a 
QALY gain despite the patient remaining in a state WTD. 
In the material here, which is based on the EQ-5D results applying the UK TTO valuation 
algorithm, about 3% of patients treated in ICU or HDU but living at home and capable of answering the 
questionnaires obtained a HRQoL score WTD. Does this really mean that those patients considered death a 
more desirable alternative than continuing to live in their present health state? We do not know, since to our 
knowledge no one has ever directly asked such patients whether they agree that their health state is WTD and 
whether they would rather die than go on living in their present health state. It is difficult to envision what 
useful information varying negative scores—e.g., -0.594 vs. -0.040—carry and the practical implications 
they might convey.  
Of course, it is also possible that a positive HRQoL score would result for someone who would 
regard her/his health as WTD with instruments generating only positive scores like 15D. Technically, it would 
be easy to scale the scores so that negative scores are also allowed. But, the question becomes: how does one 
establish a reasonable, non-arbitrary, lowest possible negative score?   
Remaining on the positive side of the scale is consistent with the ethical climate in most 
societies: even if the individual considers her/his health state WTD and even if most people would regard it as 
such, legislation does not acknowledge such states and allow people in those states to be helped to die for 
improving their quality of life. Thus, most societies assign a positive score to all health states (except, perhaps, 
for brain death) in their health policy. From this point of view, nothing is gained by allowing negative scores, 
while considerable analytical and ethical complexities are created in doing so (Sintonen, 1995).  
 
6.6 The time horizon used in QALY calculations 
 
According to previous literature and the results presented here, mortality among critical care 
patients is elevated (Hein et al., 2006; Stricker et al., 2011; Timmers et al., 2011; Shenk et al., 2012) 
indicating that the time horizon used in QALY calculations should be decided upon carefully. At present, 
different time horizons are used and the seriousness of the illness is not necessarily taken into account 
(Weintarub et al., 2003; Al-Ruzzeh et al., 2008; Graf et al., 2008; Linko et al., 2010).  
The use of the follow-up time as a time horizon might result in inaccuracies due to censoring 
and possible long-lasting excess mortality. An additional disadvantage is that the possible complications of 
the demanding care process, which may last for the entirety of the remaining lifespan, are accounted for in 
the calculations for a limited period of time only. In principle, one purpose of critical care is to save lives, 
which means that the effect of care lasts for the duration of a patient’s lifetime. Consequently, using life 
expectancy as a time horizon within the critical care setting is a better alternative than the follow-up time. 
The Finnish guidelines for the evaluation of medicines state that the time horizon should be long enough to 
take into account all essential costs and health effects (Pharmaceuticals Pricing Board, 2011).   
The annual RSR makes it possible to decipher the potential annual excess mortality compared 
to an age- and sex-standardised population-specific mortality. According to the results here, general critical 
care patients experienced excess mortality during the entire follow-up period; but, in scheduled cardiac 
surgery patients, the mortality was almost comparable to the population’s mortality. Consequently, the 
excess mortality of patients in intensive care is dependent on the form of care and should be assessed 
according to diagnostic group or form of care.  
The estimation of the life expectancy for patients using the bias-reduced method—i.e., in 
narrow age groups—turned out to be useful, since it was possible to estimate the age-specific reduction in 
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lifetime in patient groups with excess mortality. This is clearly a methodological improvement adding to the 
credibility of the estimation of life expectancy compared to previous methods used to adjust for excess 
mortality, where a fixed number or proportion of life years was reduced from the general population’s life 
expectancy regardless of age (Malmivaara et al., 2011; Talmor et al., 2008). In addition, this made it possible 
to overcome the use of concurrent reductions in lifetime, the relevance of which from the point of view of 
life expectancy is dependent on age.   
The approach used here also allows for the extrapolation of life expectancy using different 
mortality rates depending on whether the mortality rate after the follow-up time is equal to that of the 
population or whether varying degrees of excess mortality remain for the duration of one’s lifetime. This is 
an important advantage since excess mortality does not necessarily end at the same time as follow-up and 
may continue for unspecified time periods. In addition, the length of the follow-up time had an effect on the 
extrapolated life expectancy; thus, sensitivity analyses are particularly important in illnesses with high 
mortality rates when follow-up times are limited. 
In addition to illustrating excess mortality, the annual RSR can also reveal reduced mortality. 
For example, in ageing populations evaluated as fit enough to undergo demanding forms of care, the age-
standardised population’s life expectancy might not be similar to that of the patients. Furthermore, in an 
ageing population, the mortality rate is naturally high and the reported high mortality rate can be incorrectly 
associated with the treatment under evaluation even though it is a consequence of the patients’ age.   
 
6.7 Factors affecting the follow-up HRQoL 
 
The probability of death and the follow-up HRQoL were predicted by different factors. None 
of the CSICU-related morbidity or mortality factors, such as renal or respiratory complications, predicted the 
follow-up HRQoL. Given that a good HRQoL is an important objective of health care, its evaluation 
demands HRQoL-specific indicators. Previous research (Deja et al., 2006; Davydow et al. 2009; Loponen et 
al., 2008; Ringdal et al., 2009) has indicated that variables predicting the mortality risk are not valuable in 
the prediction of follow-up HRQoL within the critical care setting. Instead, patients’ subjective experiences 
during treatment have been found to be important from the point of view of the follow-up HRQoL.  
When calculating the number of QALYs as a measure of the effectiveness of care, it is 
important to identify factors affecting the follow-up HRQoL. The existence of such factors might enhance or 
dilute the actual effect of the care delivered, i.e., follow-up HRQoL scores are improved or impaired due to 
other factors than the care delivered. The study reported on here suggests that restlessness experienced 
during an ICU stay has a detrimental effect on the follow-up HRQoL. This result is consistent with those 
from earlier studies that have reported the negative effect of restlessness during a hospital stay on subsequent 
HRQoL (Davydow et al., 2008; Ringdal et al., 2009). Routine follow-up for restlessness during ICU 
treatment might help to identify patients in need of individualised care and, thus, increase the possibility of 
the nursing staff facilitating patients receiving the maximum benefit from treatment.  
The finding that severe or unbearable pain experienced during an ICU stay has a negative 
effect on the post-operative HRQoL is to our knowledge new. This suggests that the management of pain 
should be one of the key areas of focus during the post-operative treatment period among cardiac surgery 
patients. However, our results must be regarded as preliminary and need to be confirmed in future. 
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6.8 Limitations of the study 
 
The aim of the studies reported here was to evaluate the effect of different assumptions 
concerning the components of the quantification of QALYs in critical care setting. The results are based on 
empirical data gathered during an ordinary care process. The low response rate can be regarded as a 
limitation; but, since the objective of the studies was not to generalise the results to critical care setting 
(studies I, II and III), but instead to determine and illustrate the effect of calculation methods on the number 
of QALYs, the response rate is not a major cause of concern. The response rate in study IV, the objective of 
which differed from that for the other studies, was acceptable and the differences between respondents and 
non-respondents were relatively minor. Consequently, the results can be considered reliable.  
The lack of a baseline HRQoL score is a major limitation related to the comparison of 
instruments’ responsiveness to change (study I) and to the calculation of QALYs (study II). Obviously, the 
change in the HRQoL score would have been more prominent and the difference in the change score 
between instruments might have been more pronounced if it would have been assessed in a before–after 
design instead of evaluating HRQoL twice after treatment, i.e., at 6 and 12 months after ICU treatment. 
Despite this, the results here revealed differences between the instruments in several respects. In retrospect, 
proxy baseline assessments should have been performed in more than 100 patients, since the number of such 
evaluations was rather low in some of the diagnostic groups. As a consequence, our baseline assessment 
results should not be used as a standard for critical care patients, but rather as a theoretical example only. 
Regardless, the results of the baseline assessment reflect the differences between the instruments and show 
that baseline HRQoL scores may vary according to the diagnostic group of acutely ill patients.  
The rule of rescue applies in critical care and, therefore, we do not know what would happen 
to patients in terms of the length and quality of life through “conventional” treatment alone. This is also 
difficult to establish, since it would be unethical to organise a trial where patients were randomised to receive 
ICU/HDU or conventional treatment in most cases. Consequently, studies evaluating the effectiveness of 
critical care must always be based on assumptions. To be able to compare the cost-effectiveness of 
treatments across a variety of medical specialties, similar assumptions should be used irrespective of whether 
care is provided on an emergency or elective basis. Because it is difficult to say which assumption set is most 
realistic in the critical care setting, there is a clear need for sensitivity analyses applying assumption sets 
when reporting the results of studies. 
There was a slight selection bias in study I, since the inclusion criterion was survival time of 
at least 12 months and, as is known, 1-year mortality is elevated in the target patient group. This might have 
an impact on the magnitude of the observed ceiling effect using the EQ-5D, but not on the interpretation of 
differences between instruments. On the other hand, the slightly selected patient population—i.e., patients 
with quite a good survival rate—had scores consistent with health states WTD indicating that the EQ-5D can 
produce negative HRQoL scores even in fairly well-off patients. The selected data might explain the lack of 
very low HRQoL scores using the 15D. 
In study II, hospital admission was assumed to have occurred on an emergency basis if the 
admission to both the hospital and ICU or HDU occurred on the same day. Consequently, the study 
population may also include some scheduled surgical patients who were admitted to the hospital on the day 
of the procedure, an conversely some acutely ill hospitalised patients may have been excluded from the data 
set. The comparison of the diagnoses observed in studies I and II, however, suggests that most of the patients 
were acutely ill in study II.  
The follow-up time was restricted to a maximum of 12 months in studies dealing with 
HRQoL. Particularly in the study dealing with QALY calculations (study II), the restricted follow-up time in 
addition to other assumptions applied materialises as high cost per QALY ratios. However, the objective of 
this particular study was not to establish the cost utility of critical care, but to demonstrate the effects of 
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differences between calculation methods and instruments. A follow-up time of 12 months, instead of the 6 
months used in study III, might have allowed for a better assessment of the permanence of the experienced 
restlessness and severe or unbearable pain. Due to the preliminary character of the study, this could not be 
anticipated beforehand. Additionally, the prevalence of experienced restlessness and severe or unbearable 
pain may have been higher if they had been assessed during their stay in the ward as well.  
In study IV, the initial patient population included numerous patients; but, the high 30-day 
mortality rate reduced the patient population and analyses of narrow age groups were not possible for all 
diagnostic groups, especially, women. If the patient population had been large enough, the presented values 
in the tables concerning life expectancy among narrow age groups could have been even more useful for 
other studies within critical care settings.  
 
6.9 Clinical implications 
 
The findings here corroborate the notion that QALY is not a universal measure. This should 
be taken into account when evaluating the effectiveness of different forms of care. In addition, the results 
here expand the knowledge concerning the effect of methods used in QALY calculations and, thus, promote 
the critical evaluation of published cost-utility studies and the design of future cost-utility studies.   
Reporting just the average number of QALYs gained may be insufficient, since in general 
there are patients for whom their HRQoL improves, remains unchanged or even deteriorates. As a 
consequence, the objective of utility studies should be, in addition to analysing the patient population as a 
group, to determine the reasons for the variation in treatment results between patients. It is important to 
establish which factors explain patient-specific variation. That is, are they explained by patient-related 
factors or are they explained by care process–related factors. The identification of such factors would likely 
improve patient selection and promote the development of the care process. 
It is essential to understand that the HRQoL scores produced using different instruments are 
not interchangeable. In addition, the quite congruent average HRQoL scores produced using various 
instruments might conceal largely divergent distributions. Consequently, results from different HRQoL 
instruments cannot be combined and the distribution of HRQoL scores should be reported preferably in a 
graphical form as well.The annual relative survival method takes into account the mortality of the general 
population. Consequently, the excess mortality related to treatment can be identified without obtaining cause 
of death data. This is valuable with respect to elderly persons whose mortality from natural causes is high.  
 
6.10 Future studies 
 
There is a demand for future studies concerning the baseline HRQoL scores used in the 
critical care setting, the long-term mortality and HRQoL-related indicators. The patient-reported baseline 
HRQoL is impossible to obtain from all patients within critical care, necessitating a different solution to this 
particular problem. One possibility to resolve this issue might be to determine baseline values based on age 
group, sex and diagnosis and using these values across studies. However, the comparability between acutely 
ill and scheduled patients should be guaranteed. 
Generally, funding for such studies is limited resulting in limited follow-up times and the need 
to resort to incomplete data sets. To resolve this particular problem, the compilation of a life table based on 
retrospective data might be useful for the determination of life expectancy for different studies. The life table 
should include diagnosis, sex, age group, the duration of excess mortality and extrapolated life expectancy. 
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There is some evidence that the follow-up HRQoL is predicted by factors other than those which predict 
morbidity and mortality. Since HRQoL is in itself an important objective of health care, it is essential to 
establish more conclusively in future studies which factors before and during treatment are important 
predictors of follow-up HRQoL.  
Some HRQoL instruments—in particular, the EQ-5D—produce a negative HRQoL score for 
many patients, which imply that their health state is worse than being dead. Considering the credibility of 
such scores and of the entire instrument, it would be necessary to carry out a study where patients who have 
obtained a negative score would be asked directly whether they agree that their health state is worse than 
being dead and whether they would rather die than go on living in their present health state. 
Different types of modelling—e.g., decision trees, Markov models and Monte Carlo 
simulations—are not yet commonly used to estimate cost utility in critical care settings. The data for 
modelling studies—i.e., information on outcomes, their probabilities, HRQoL scores, QALYs and costs 
associated with specific outcomes over time—are usually collected from diverse sources. It would be 
interesting to compare the results of such studies with those of prospective follow-up studies. Yet, the 
conclusions regarding the measurement of HRQoL and QALYs in this study also apply to modelling studies.   
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7.  Conclusions 
Studies based on empirical data demonstrated that QALY is not a universal measure. Instead, 
it is affected by how the factors to be taken into account in the calculation of QALYs are chosen and defined. 
Therefore, the calculation methods of QALYs should ideally be standardised. This may be difficult to 
achieve. At the very least, in each study using QALYs, the components used in their calculation should be 
clearly reported.  
The methods and assumptions used in QALY calculations vary from study to study making 
comparisons between different studies difficult if not altogether impossible. When reporting the number of 
QALYs in a critical care setting, as a minimum the following elements should always be reported: how the 
baseline HRQoL was assessed, in which way recovery was assumed to take place, what calculation method 
was used (i.e., QALYs experienced or gained) and what measurement points including follow-up time and 
time horizon were used. When reporting the cost per QALY ratio, both the average or incremental as well as 
the costing methodology should be specified — that is, which resource items were included and how they 
were valued.  
The method for assessing QALYs gained should be favoured over those methods which assess 
QALYs experienced, and the measurement points used should relate to the expected recovery of patients. 
The ranking of different health-care interventions in terms of their effectiveness calls for standardisation in 
the calculation of QALYs. The ranking of different interventions in terms of their cost utility (average cost-
utility ratio) requires additional standardisation of the costing methodology. If societies define thresholds for 
acceptable incremental cost-utility ratios, they should be HRQoL instrument–specific given that different 
instruments, when used concurrently, produce different estimates for QALYs gained. 
Factors affecting the follow-up HRQoL also influence the number of QALYs gained or 
experienced. Research to determine such factors should be carried out among different patient populations 
and environments. To improve the transparency and usefulness of HRQoL studies, the distribution of 
HRQoL scores and the proportion of patients who benefited from treatment as well as those who did not 
should be reported.  
From the point of view of the QALY concept, negative HRQoL scores are problematic. The 
negative scores cause illogical outcomes and are difficult to interpret and act upon. In the field of health 
economics, consensus is needed in order to resolve these issues. 
The annual RSR and the extrapolation of life expectancy are valuable methods in the 
estimation of life expectancy especially in patient populations with a high mortality rate and in ageing 
populations. Such methods increase the precision of QALY calculations. 
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